## 1 Brain/MINDS Beyond Human Brain MRI Study: Multi-Site Harmonization for Brain

2

## **Disorders Throughout the Lifespan**

3 Running Head: Brain/MINDS Beyond MRI study

4

5 Shinsuke Koike, M.D., Ph.D.<sup>1,2,3,4</sup>; Saori C Tanaka, Ph.D.<sup>5</sup>; Tomohisa Okada, M.D., Ph.D.<sup>6</sup>;

- Toshihiko Aso, M.D., Ph.D.<sup>7</sup>; Michiko Asano, Ph.D.<sup>1</sup>; Norihide Maikusa, Ph.D.<sup>1,8</sup>; Kentaro
- 7 Morita, M.D., Ph.D.<sup>9</sup>; Naohiro Okada, M.D., Ph.D.<sup>2,4,10</sup>; Masaki Fukunaga, Ph.D.<sup>11</sup>; Akiko
- 8 Uematsu, Ph.D.<sup>1</sup>; Hiroki Togo, MSc.<sup>8</sup>; Atsushi Miyazaki, Ph.D.<sup>12</sup>; Katsutoshi Murata, MSc.<sup>13</sup>;
- 9 Yuta Urushibata, MSc.<sup>13</sup>; Joonas Autio, Ph.D.<sup>7</sup>; Takayuki Ose, MSc<sup>7</sup>; Junichiro Yoshimoto,
- Ph.D.<sup>5</sup>; Toshiyuki Araki, M.D., Ph.D.<sup>14</sup>; Matthew F Glasser, M.D., Ph.D.<sup>15,16</sup>; David C Van
- 11 Essen, Ph.D.<sup>15</sup>; Megumi Maruyama, Ph.D.<sup>17</sup>; Norihiro Sadato, M.D., Ph.D.<sup>11</sup>; Mitsuo Kawato,
- 12 Ph.D.<sup>5,18</sup>; Kiyoto Kasai, M.D., Ph.D.<sup>2,3,4,10</sup>; Yasumasa Okamoto, M.D., Ph.D.<sup>19</sup>; Takashi
- 13 Hanakawa, M.D., Ph.D.<sup>8,20</sup>; Takuya Hayashi, M.D., Ph.D.<sup>7</sup>; Brain/MINDS Beyond Human Brain
- 14 MRI Group
- 15
- 16 1) Center for Evolutionary Cognitive Sciences (ECS), Graduate School of Art and Sciences, The
- 17 University of Tokyo, Meguro-ku, Tokyo 153-8902, Japan
- 18 2) University of Tokyo Institute for Diversity & Adaptation of Human Mind (UTIDAHM),
- 19 Meguro-ku, Tokyo 153-8902, Japan
- 20 3) University of Tokyo Center for Integrative Science of Human Behavior (CiSHuB), 3-8-1
- 21 Komaba, Meguro-ku, Tokyo 153-8902, Japan
- 4) The International Research Center for Neurointelligence (WPI-IRCN), Institutes for
- 23 Advanced Study (UTIAS), University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654,
- 24 Japan
- 25 5) Brain Information Communication Research Laboratory Group, Advanced
- 26 Telecommunications Research Institutes International (ATR), Kyoto 619-0288, Japan
- 27 6) Human Brain Research Center, Kyoto University, Kyoto 606-8507, Japan
- 28 7) Laboratory for Brain Connectomics Imaging, RIKEN Center for Biosystems Dynamics
- 29 Research, Hyogo 650-0047, Japan
- 30 8) Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, Kodaira-shi,
- 31 Tokyo 187-8551, Japan
- 32 9) Department of Rehabilitation, Graduate School of Medicine, The University of Tokyo,
- 33 Bunkyo-ku, Tokyo 113-8655, Japan
- 10) Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo,
- 35 Bunkyo-ku, Tokyo 113-8655, Japan
- 36 11) Division of Cerebral Integration, Department of System Neuroscience, National Institute for
- 37 Physiological Sciences, Okazaki 444-8585, Japan
- 3812) Tamagawa University Brain Science Institute, 6-1-1 Tamagawagakuen, Machida, Tokyo
- 39 194-8610, Japan
- 40 13) Siemens Healthcare K.K. Shinagawa-ku, Tokyo 141-8644, Japan
- 41 14) Department of Peripheral Nervous System Research, National Institute of Neuroscience,
- 42 National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8551, Japan
- 43 15) Department of Neuroscience, Washington University School of Medicine, St Louis, Missouri
- 44 USA

- 45 16) Department of Radiology, Washington University School of Medicine, St Louis, Missouri,
- 46 USA
- 47 17) Research Enhancement Strategy Office, National Institute for Physiological Sciences,
- 48 Okazaki 444-8585, Japan
- 49 18) Center for Advanced Intelligence Project, RIKEN, Tokyo 103-0027, Japan
- 50 19) Department of Psychiatry and Neurosciences, Hiroshima University, Hiroshima 734-8551,
- 51 Japan
- 52 20) Department of Integrated Neuroanatomy and Neuroimaging, Kyoto University Graduate
- 53 School of Medicine, Kyoto 606-8303, Japan
- 54

# 55 <u>Corresponding to:</u>

- 56 Takuya Hayashi, M.D., Ph.D.
- 57 Laboratory for Brain Connectomics Imaging,
- 58 RIKEN Center for Biosystems Dynamics Research
- 59 6-7-3 Minatojima-minami-machi, Chuo-ku, Kobe, Hyogo 650-0047
- 60 E-mail: <u>takuya.hayashi@riken.jp</u>
- 61 Tel: +81-78-304-7140
- 62 Fax: +81-78-304-7141

## 63 Abstract

Psychiatric and neurological disorders are afflictions of the brain that can affect individuals 64 65 throughout their lifespan. Many brain magnetic resonance imaging (MRI) studies have been conducted; however, imaging-based diagnostic and therapeutic biomarkers are not yet well 66 67 established. The Brain/MINDS Beyond human brain MRI project (FY2018 ~ FY2023) is a 68 multi-site harmonization study aiming to establish clinically-relevant imaging biomarkers using multiple high-performance scanners, standardized multi-modal imaging, and a study design that 69 70 includes traveling subjects. This project began with 13 clinical research sites that collect MRI 71 data on psychiatric and neurological disorders across the lifespan and three research sites that 72 design and develop measurement procedures, neuroimaging protocols, data storage and sharing, 73 and analysis tools. Brain images obtained with the Harmonization protocol (HARP) are preprocessed and analyzed using approaches developed by the Human Connectome Project, 74 75 generating preliminary cortical structure, function, and connectivity measures that are 76 comparable across scanners. The use of 'travelling subjects', in which study participants travel to multiple sites to undergo scanning with standardized neuroimaging techniques, enable us to 77 78 minimize the measurement bias between scanners and protocols and to increase the sensitivity 79 and specificity of case-control studies. All the imaging and demographic and clinical data are 80 shared between the participating sites and will be made publicly available in 2024. To the best of 81 our knowledge, this is the first multi-site human brain MRI project to explore multiple 82 psychiatric and neurological disorders across the lifespan. The Brain/MINDS Beyond human 83 brain MRI project will help to identify the common and disease-specific pathophysiology 84 features of brain diseases and develop imaging biomarkers for clinical practice.

# 85 <u>Keywords</u>

- 86 Multi-site Study; HCP-style Brain Imaging; Psychiatric Disorders; Neurological Disorders;
- 87 Harmonization Protocol; Traveling Subjects

- 88 <u>Text</u>
- 89 Abbreviations
- 90 DALYs, disability-adjusted life years
- 91 MRI, magnetic resonance imaging
- 92 HCP, Human Connectome Project
- 93 ABCD, Adolescent Brain Cognitive Development
- 94 BPD, bipolar disorder
- 95 MDD, major depressive disorder
- 96 DecNef, Decoded Neurofeedback
- 97 ASD, autism spectrum disorder
- 98 ADNI, Alzheimer's Disease Neuroimaging Initiative
- 99 AD, Alzheimer's disease
- 100 MCI, mild cognitive impairment
- 101 PPMI, Parkinson's Progression Markers Initiative
- 102 PD, Parkinson's disease
- 103 T1w, T1-weighted
- 104 T2w, T2-weighted
- 105 rsfMRI, resting state functional MRI
- 106 CRHD, Connectome Related to Human Disease
- 107 GLM, general linear model
- 108 TS, traveling subject
- 109 AMED, Japan Agency for Medical Research and Development
- 110 Brain/MINDS Beyond, Strategic International Brain Science Research Promotion Program

- 111 HARP, Harmonization protocol
- 112 DWI, diffusion-weighted imaging
- 113 QC, quality control
- 114 MNI, Montreal Neurological Institute
- 115 MSM, multi-modal surface matching
- 116 GLMM, general linear mixed model
- 117 CIFTI, Connectivity Informatics Technology Initiative
- 118 FEF, frontal eye field
- 119 PEF, premotor eye field
- 120 PSL, peri-sylvian language
- 121 STS, superior temporal sulcus
- 122 NODDI, nerite orientation and density imaging

## 123 **1. Introduction**

124 Psychiatric and neurological disorders are afflictions of the brain that can affect individuals 125 throughout their lifespans. Using the disability-adjusted life years (DALYs), which is a measure 126 of disease burden proposed by the World Health Organization Global Burden of Disease study, 127 in 2010 mental and behavioral disorders accounted for 7.4% of the total DALYs and 128 neurological disorders accounted for 3.0% (Murray et al., 2012), up from 5.4% and 1.9% in 129 1990, respectively. Since the 1990s, technical advances in magnetic resonance imaging (MRI) 130 have allowed detailed analysis of the organization of brain function and structure in humans. 131 Recent high-quality MRI studies with a large cohort are expected to provide neurobiological and life-span information in healthy subjects (Glasser et al., 2016b; Harms et al., 2018; Miller et al., 132 133 2016), which will hopefully provide diagnostic utility for patients with psychiatric and 134 neurological disorders (Drysdale et al., 2017; Elliott et al., 2018b; Koutsouleris et al., 2015; 135 Nunes et al., 2018). However, the diagnostic value of brain MRI in psychiatric disorders has not 136 yet been established, presumably because effect sizes tend to be small and overlap with 137 variability in healthy individuals (Yamashita et al., 2019). Protocols of scanning and analysis 138 have rarely been standardized across projects, though that has begun to change - especially for 139 large projects such as the Human Connectome Project (HCP; (Van Essen et al., 2012)), UK 140 Biobank (Miller et al., 2016), and the Adolescent Brain Cognitive Development (ABCD) project 141 (Casey et al., 2018).

142

143 1.1. Previous multi-site neuroimaging studies for neuropsychiatric disorders

144 Several brain imaging projects have attempted to identify suitable biomarkers in

145 neuropsychiatric diseases. Recent multi-site neuroimaging mega studies have revealed well-

146	replicated and clinically applicable findings from structural images; the Enhancing
147	NeuroImaging Genetics through Meta-Analysis Consortium in the U.S. $(n = 4,568)$ and the
148	Cognitive Genetics Collaborative Research Organization in Japan ( $n = 2,564$ ) replicated findings
149	that patients with schizophrenia have volumetric alterations of subcortical structures when
150	compared to healthy controls (Okada et al., 2016; van Erp et al., 2016). The findings were partly
151	evident in other psychiatric disorders, such as bipolar disorder (BPD) and major depressive
152	disorder (MDD) (Hibar et al., 2018; Schmaal et al., 2017; Schmaal et al., 2016; van Erp et al.,
153	2016). Using resting-state functional MRI (rsfMRI), a multi-site study successfully developed
154	generalized classifiers for psychiatric disorders. The Decoded Neurofeedback (DecNef) Project
155	( <u>https://bicr.atr.jp/decnefpro/</u> ), a multi-site neuroimaging study in Japan (12 sites, $n = 2,409$ ),
156	developed a generalized classifier for autism spectrum disorder (ASD) with a high accuracy—
157	not only for the data in three Japanese sites (85%) but also for the Autism Brain Imaging Data
158	Exchange dataset (75%) (Yahata et al., 2016). The project also quantified the spectrum of
159	psychiatric disorders by applying the ASD classifier to other multi-disorder datasets
160	(schizophrenia, MDD, and attention-deficit/hyperactivity disorder). Therefore, the focus of
161	mega-analyses is shifting from features found in case-control studies to cross-disease
162	comparisons that can identify common and disease-specific features.
163	In the field of neurodegenerative disease, the Alzheimer's Disease Neuroimaging
164	Initiative (ADNI) is one of many major multi-site neuroimaging and biomarker studies of
165	Alzheimer's disease (AD) and mild cognitive impairment (MCI) that was started in 2005 in
166	North America (Mueller et al., 2005; Weiner et al., 2015). It contributed to the development of

- 167 blood and imaging biomarkers, the understanding of the biology and pathology of aging, and to
- 168 date has resulted in over 1,800 publications. ADNI also impacted worldwide ADNI-like

169	programs in many countries including Japan, Australia, Argentina, Taiwan, China, Korea,
170	Europe, and Italy. The Japanese ADNI (J-ADNI) conducted a multi-site neuroimaging study on
171	cognitively normal elderly patients, MCI, and mild AD ( $n = 537$ ), which emphasized the
172	harmonization of the protocol and procedures with the ADNI (Iwatsubo et al., 2018). J-ADNI
173	also developed machine learning techniques using feature-ranking, a genetic algorithm, and a
174	structural MRI-based atrophy measure to predict the conversion from MCI to AD (Beheshti et
175	al., 2017). Inspired by the Parkinson's Progression Markers Initiative (PPMI; (Parkinson
176	Progression Marker Initiative, 2011), the Japanese (J-) PPMI team has also started a cohort in
177	patients with rapid eye movement sleep behavioral disorder, which is regarded to be prodromal
178	to Parkinson's disease (PD) (Mukai and Murata, 2017).
179	These previous mega-studies have contributed to the discovery of potential mechanisms
180	and biomarkers of multiple brain disorders. However, most of these imaging biomarkers have a
181	relatively small effect sizes and the study results were drawn from multi-site data which are often
182	heterogenous and used now outdated traditional low-resolution data acquisition protocols. In
183	addition, there have been no human brain MRI studies that explore multiple psychiatric and
184	neurological disorders that occur through the lifespan within the same cohort of subjects.
185	
186	1.2. High-quality multi-modal MRI protocols and preprocessing pipelines
187	The HCP developed a broad approach to improving brain imaging data acquisition,
188	preprocessing, analysis, and sharing (Glasser et al., 2016b). It includes: 1) high-quality multi-
189	modal data acquisition; 2) in a large number of subjects; and 3) high-quality data preprocessing
100	and has proven usefulness of MPI techniques for understanding the detailed ergenization of a

and has proven usefulness of MRI techniques for understanding the detailed organization of a

191 healthy human brain (Elliott et al., 2018a; Glasser et al., 2016a; Smith et al., 2015). The HCP

192	aimed to delineate the brain areas and characterize neural pathways that underlie brain function
193	and behavior in 1,200 healthy young adults (Van Essen et al., 2012). HCP scans were performed
194	by a single MR scanner (a customized 3T Skyra, Siemens Healthcare GmbH, Erlangen,
195	Germany) in a total of 4-hour scan time for high-resolution multi-modal data, which included
196	T1-weighted (T1w) images, T2-weighted (T2w) images, diffusion-weighted images (DWI),
197	rsfMRI, and task fMRI (Glasser et al., 2016b; Glasser et al., 2013). The HCP also developed a
198	set of preprocessing pipelines with improved cross-subject alignment that dramatically improves
199	the spatial localization of brain imaging findings and also increasing statistical sensitivity
200	(Coalson et al., 2018; Glasser et al., 2013; Robinson et al., 2018). For the Lifespan Developing
201	and Aging HCP Projects (HCP-D and HCP-A) the original HCP protocol for healthy young
202	adults was shortened, for children and the elderly (60 to 90 min scan time; (Bookheimer et al.,
203	2019; Harms et al., 2018; Somerville et al., 2018), and for psychiatric and neurological disorders
204	(the Connectomes Related to Human Disease [CRHD];
205	https://www.humanconnectome.org/disease-studies), and adolescent development (the ABCD
206	project; (Casey et al., 2018). The UK Biobank used an even more abbreviated scanning approach
207	to collect a much larger number of cohort ( $n = 100,000$ ) to predict health conditions (Miller et
208	al., 2016).
209	Many of these high-quality multimodal projects have been based on a single or small
210	number of the same model scanners at different sites and thus did not fully address

standardization of the data acquisition across different scanner models or vendors. We aim to

accelerate harmonization technologies to be used in at least five scanner platforms by combining

213 approaches to high-quality imaging acquisition, preprocessing, study design, and statistical bias

214 correction to potentially improve the sensitivity and validity of imaging biomarkers.


215

## 216 *1.3. Traveling subjects*

217 A harmonization approach is required for individual-based statistics using a multi-site dataset, 218 even when the brain images are obtained using the same machine and protocol, because the data 219 from each site has the bias from hardware and scanning protocol (measurement bias) and 220 sampling variability (i.e. age, sex, handedness, and socioeconomic status). If measurement biases 221 were correlated or anti-correlated with a specific disease state this would result in a positive or 222 negative bias in a given measure, whereas uncorrelated biases would merely reduce sensitivity 223 (i.e. SNR) of the measure. Sampling biases due to biological differences in the sampled 224 populations should also be considered for both case and control groups. Data harmonization has 225 been proposed to control for these biases, including a general linear model (GLM) with the site 226 as the covariate, a Bayesian approach (Fortin et al., 2018; Fortin et al., 2017), and a meta-227 analytic approach (Okada et al., 2016; van Erp et al., 2016), but the methods used for controlling 228 both biases are unable to distinguish between them (Yamashita et al., 2019). Inter-site cross-229 validation by machine learning and deep learning techniques is a method that aims to remove 230 bias without any specific preparation if large-sample datasets are available (Nunes et al., 2018). 231 However, this method extracts stable characteristics across the images and is limited to using 232 only a part of the information for further analysis. In addition, it is unclear whether the classifiers 233 obtained by such methods can be applied to an independent new site of the initial multi-site 234 project.

The traveling subject (TS) approach is a powerful research design to control for site differences (Figure 1). This approach requires the images from the same participants at all the participating sites, but also requires significant effort from the sites and the participants when

238 compared to other harmonization methods listed above, and the TS scans must be completed 239 before the analysis starts. However, the TS approach can differentiate most of the sample 240 variability from measurement bias (Yamashita et al., 2019). The DecNef Project explored 241 rsfMRI functional connectivity for multiple psychiatric diseases and scanned nine TS 242 participants who received repeated MRI measurements at all sites. Measurement and sampling 243 biases for each group (schizophrenia, MDD, ASD, and healthy controls) were segregated from 244 individual and disease-specific factors as the rest of sampling variability. The results showed that 245 the effects of both bias types on functional connectivity were greater than or equal to those of 246 disease-specific factors. With regard to measurement bias, differences in phase encoding 247 direction had the biggest effect size when compared to those of vendor, coil, and scanner within 248 the same vendor. The harmonization method was estimated to reduce measurement bias by 29% 249 and improve the signal-to-noise ratio by 40% (Yamashita et al., 2019). Further investigations are 250 needed to determine the best approach for reducing sampling bias arising from biological 251 differences in the sampled population. 252



## Figure 1. Case-control studies and traveling subject approach.

(Top) When we analyze multi-site data from a set of case-control MRI studies, we must consider machine and protocol-derived bias (measurement bias) as well as sampling bias (from biological differences in the sampled populations). Even if the machine and protocol are the same between sites (e.g. Sites A and B), measurement bias may still occur because of slight differences in the magnetic or radiofrequency fields, etc. Sampling bias should be considered for patient groups as well as control groups, given that the control participants were recruited according to the demographics in the patient group. (Bottom) The traveling subject (TS) harmonization approach enables us to combine with case-control datasets by differentiating between measurement and sampling biases (Yamashita et al., 2019). Based on the general linear model (GLM), TS participants need to receive measurements from all participating sites (e.g. only TS 1 dataset). To reduce the effort of TS participants and participating sites, this project applies a general linear mixed model (GLMM) approach and hub-and-spoke model to the TS project. With this approach, all participants receive scans at one or more hub sites (site A), and measurement bias is calculated using multiple TS datasets by means of a GLMM (TS 1 and 2).


253

## 254 1.4. Brain/MINDS Beyond project

255 The Strategic International Brain Science Research Promotion Program (Brain/MINDS Beyond; 256 FY2018–FY2023; https://brainminds-beyond.jp/) was funded by the Japan Agency for Medical 257 Research and Development (AMED) to support global brain research by enhancing collaboration 258 with the domestic projects of other countries. Brain/MINDS Beyond consists of four research 259 groups: G1-1, Identification of the pathogenic mechanism of psychiatric and neurological 260 disorders through the acquisition and analysis of brain MRI-scan images and clinical data 261 (Developmental [G1-1D], adult [G1-1A], and senescent [G1-1S] stages); G1-2, Brain MRI data 262 acquisition, analysis, and informatics; G2, Research involving an inter-species comparison of 263 human and nonhuman primate brains by structural and functional parcellation and homology 264 analyses; and G3, Development and application of technologies, such as neuro-feedback through 265 collaboration with artificial intelligence research projects as well as the Innovative Research 266 Group. In human brain imaging, G1-1 intends to measure human participants, including patients 267 with neuropsychiatric disorders, across the lifespan, and G1-2 intends to coordinate and support 268 data acquisition, storage, preprocessing, analysis, and distribution (Figure 2 and Table 1). The 269 Brain/MINDS Beyond MRI working group also set up a standardized procedure for MRI data 270 acquisition (Harmonization protocol [HARP]) and clinical and neurocognitive data assessment 271 (Tables 2 and 3). Following previous multi-site studies in Japan (Iwatsubo et al., 2018; Okada et 272 al., 2016; Yahata et al., 2016; Yamashita et al., 2019), the overall goal is to find an altered brain 273 imaging characteristics in psychiatric and neurological disorders that can be applied to future 274 therapeutic investigations and clinical devices. To address limitations of previous findings in 275 multi-site studies, we are using high performance research-based MRI scanners and we modeled 276 our multi-modal protocol (T1w images, T2w images, diffusion-weighted imaging [DWI], 277 rsfMRI, task fMRI, quantitative susceptibility mapping, and arterial spin labeling) on that used

by the HCP and ABCD study projects. We are also obtaining a TS dataset for the harmonization
of the clinical MRI datasets and the development of technical tools to harmonize the multi-site
data. Once the project period ends, the data will be openly distributed to researchers via a public
database.

Here, we introduce the Brain/MINDS Beyond human brain MRI project and show preliminary results in high-quality neuroimaging using the TS data that is amenable to harmonization. We then discuss our plans for investigating the neural basis of psychiatric and neurological disorders in the hope of developing therapeutic targets and devices that are applicable to clinical settings.



# Figure 2. Brain/MINDS Beyond human brain MRI project.

Institutes in the blue boxes show measurement and analysis sites for neuropsychiatric disorders, and those in the orange boxes show analysis support sites. Institutes listed in boxes with a colored background represent participation in the traveling subject project.

## 288 2. Brain/MINDS Beyond human brain MRI study

### 289 2.1. Participating sites and target population

290 As of March 2020, 13 sites have approved this study project, received approval from their 291 respective ethical review board(s), and obtained clinical and TS measurements using the 292 appropriate MRI scanners (Table 1). Of these, 5 sites mainly explore psychiatric disorders 293 (schizophrenia, ASD, MDD, and BPD), 4 sites neurological disorders (AD, PD, multiple system 294 atrophy, progressive supranuclear palsy, chronic pain disorder, and epilepsy), and 2 sites both 295 categories. Two sites measure the general adolescent population to investigate brain development 296 and recruit through advertisement and cohort studies (Ando et al., 2019; Okada et al., 2019). 297 Each site intends to obtain brain images and demographic (and clinical) characteristics for 298 clinical cases and match controls for age, sex, premorbid IQ or educational attainment, socio-299 economic status, and handedness (See Cognitive and behavioral assessment section). The 300 exclusion criteria were set by each study purpose (i.e. low premorbid IQ, history of loss of 301 consciousness for more than 5 min, illegal drug use, and alcohol dependency). Illegal drug use 302 can be a major concern for disease onset and poor prognosis, especially for psychiatric disorders. 303 However, there is far less illegal drug use in Japan compared to Western European countries 304 (Degenhardt et al., 2008; Lee and Kwon, 2016), and most of the participating sites excluded 305 those with a current illegal drug use or previous history of regular use (Koike et al., 2013). 306 For the TS project, 75 healthy adults planned to undergo 6 to 8 scans at three or more 307 sites within 6 months (See Traveling Subject Project section). Five or more participants per site 308 were recruited. Each participant received test-retest scans at the recruitment site and underwent 309 scans at different sites including a hub site. We set up three hub sites, according to a hub-and-

- 310 spoke model, in which all participants received scans using a MAGNETOM Prisma scanner
- 311 (Siemens Healthcare GmbH, Erlangen, Germany) and the CRHD and HARP protocols.

Site	Research	Role	MRI scanner	Protocol	Main target
	group		(System version)		population
UTK	G1-1D,	Data	Prisma (VE11C)	CRHD	Adolescent cohort,
	G1-2	acquisition/Analysis			HP, ASD, Sch, MDD,
					Epilepsy
UTI	G1-1D,	Data	Prisma (VE11C)	CRHD	HP, ASD, Sch, MDD,
	G1-2	acquisition/Sharing			BPD
ATR	G1-2, G3	Data	Prisma (VE11C)	CRHD	HP
		acquisition/Sharing/			
		Analysis			
FUM	G1-1S	Data acquisition	Skyra (VE11C)	HARP	HP, AD, PD
TMG	G1-1D	HARP setup/Data	Trio (VB19A)	HARP	Adolescent cohort
		acquisition			
SWA	G1-1D,	HARP setup/Data	Skyra (VE11E)	HARP	HP, ASD
	G3, IR	acquisition			
NCNP	G1-1S	HARP setup/Data	Verio Tim+Dot	HARP	HP, Sch, MDD, AD,
		acquisition/Sharing/	(VD13A)		PD
		Analysis			
JTD	IR	Data acquisition	Prisma (VE11C)	HARP	HP, Chronic pain
UOS	G2	Data acquisition	Prisma (VE11C)	HARP	HP, PD, MSA, PSP
UHI	G1-1A,	HARP setup/Data	Skyra (VE11C)	HARP	HP, MDD, BPD
	G3	acquisition			
UNG	BM	Data acquisition	Verio (VB17A)	HARP	HP, Sch
UKY	G1-1S	HARP setup/Data	Skyra (VE11C)	HARP	HP, AD, PD
		acquisition			
KRC	G1-1A	Data acquisition	Verio (VB17A)	HARP	HP, Sch, MDD, BPD
BDR	G1-2	HARP setup/Data	Prisma (VE11C)	HARP	NA
		Analysis			

312	Table 1. Participating sites of the Brain/MINDS Beyond MRI project.
• • =	

313 Abbreviations: UTK, The University of Tokyo ECS (Komaba Campus); UTI, The University of

- Tokyo IRCN; FUM, Fukushima Medical University; TMG, Tamagawa Academy & University;
- 315 SWA, Showa University; NCNP, National Center of Neurology and Psychiatry; JTD, Juntendo
- 316 Hospital; ATR, Advanced Telecommunications Research Institute International; UOS, Osaka
- 317 University; UHI, Hiroshima University; UNG, Nagoya University; UKY, Kyoto University;
- 318 KRC, Kyoto University Kokoro Research Center; BDR, RIKEN Center for Biosystems
- 319 Dynamics Research; IR, Innovative Research Group in Brain/MINDS Beyond; BM,
- 320 Brain/MINDS project; CRHD, Human Connectome Studies Related To Human Disease protocol;
- 321 HARP, harmonization protocol; HP, healthy participants; ASD, autism spectrum disorders; Sch,
- 322 schizophrenia; MDD, major depressive disorder; BPD, bipolar disorder; AD, Alzheimer's
- 323 disease; PD, Parkinson disease; MSA, multiple system atrophy; PSP, progressive supranuclear
- 324 palsy.
- 325

## 326 2.2. Harmonized brain MRI protocols

327 We developed protocols that minimize potential differences related to measurement and increase 328 the MR image sensitivity to brain organization in psychiatric and neurological disorders. From a 329 neurobiological perspective, the cerebral cortex is organized by a 2D sheet-like structure with an 330 average thickness of 2.6 mm embedded and folded in the ~1300 mL of brain volume (Glasser et 331 al., 2016b). From a neuroimaging perspective, the spatial resolution and homogeneity of the 332 images are important factors that may induce bias and error during the image analysis; these 333 include partial voluming, image distortion, errors in brain segmentation, and registration. Of 334 these, respecting spatial fidelity of neuroanatomical structures is the most important approach for 335 achieving unbiased imaging (Glasser et al., 2016b). Therefore, the spatial resolution of the 336 imaging was determined based on cortical thickness and was matched across all scanners. The 337 phase encoding direction of EPI-based functional and diffusion MRI is an important factor that 338 relates to spatial distortion (and signal loss in fMRI) in association with the polarity of the 339 direction, echo spacing, and B0 magnetic field homogeneity; therefore, we acquire a spin-echo 340 filed map with opposing phase encoding directions to enable distortion correction (Andersson et 341 al., 2003). Based on these strategies, two MRI protocols were planned for use in the project: 1) a 342 harmonized MRI protocol (HARP), which can be run on the multiple MRI scanners/sites within 343 a period of 22 to 65 min; and 2) an 'HCP style' MRI protocol used by HCP CRHD for the high-344 performance 3T MRI scanner (e.g. MAGNETOM Prisma).

The HARP was created to be used at multiple MRI scanners/sites, and it was designed to obtain high-quality and standardized brain MRI data in a 'clinically' practical window of time (Table 2 and Supplementary Table S1). The parameters of the MRI scanners were as follows: 1) static magnetic field strength of 3T; 2) multi-array head coil with 32 or more channels; and 3) ability to perform a multi-band EPI sequence provided from Center for Magnetic Resonance

350 Research, University of Minnesota with an acceleration factor of 6 (Moeller et al., 2010; 351 Setsompop et al., 2012; Xu et al., 2013). In 2019, the protocol was adapted for use with five MRI 352 scanners/systems (MAGNETOM Prisma, Skyra, Trio A Tim, Verio, and Verio Dot; Siemens 353 Healthcare GmbH, Erlangen, Germany), and we plan to expand it to different MRI 354 scanners/vendors during the project period. The HARP was intended to perform the brain scan 355 within a period of ~ 30 min using a high-resolution structural MRI scan (T1w and T2w, spatial 356 resolution of 0.8 mm) and two high-sensitive rsfMRI scans with opposing phase directions, a 357 spatial resolution of 2.4 mm, and a temporal resolution of 0.8 s for a total of 10 minutes. The 358 protocols also include optional sequences for four additional rsfMRI scans, task fMRI (Emotion and CARIT) (Winter and Sheridan, 2014), two DWI scans with opposing phase encoding 359 360 directions, quantitative susceptibility mapping, and arterial spin labeling. The minimum and 361 maximum scanning time of the HARP is 22 and 65 min, respectively (Table 2). The preliminary 362 results across scanners and multi-array coils in the same subject (ID = 9503) revealed that the 363 temporal signal-to-noise ratio (tSNR) was very high in all the scanners. The mean  $\pm$  standard 364 deviation across 32k greyordinates was  $161 \pm 80$  in the Prisma at UTK,  $155 \pm 81$  in the Verio Dot at SWA,  $151 \pm 72$  in the Skyra fit at SWA,  $151 \pm 80$  in the Verio at ATR, and  $150 \pm 74$  in 365 366 the Prisma fit at ATR; the values and their distributions were similar across scanners/sites 367 (Figure 3A).

The CRHD protocol was planned for collaboration with the HCP CRHD for the Early Psychosis Project. The HCP CRHD protocol also included high-resolution structural MRI (spatial resolution of 0.8 mm), high-resolution resting-state fMRI (spatial resolution of 2 mm) with an opposing phase encoding direction and longer scan time, and high-resolution and high angular diffusion MRI.

373	The installation of the protocols in the MRI scanners was ensured by conducting
374	hierarchical parameter checks and site visits at the beginning of the measurement period. After
375	the protocol installation, each site sent XML files of the installed protocol from the MRI scanner
376	to the protocol management site (UTK), and all the parameters were confirmed with a checksum
377	algorithm using R (R Core Team, 2018). This process was useful for validating the protocols
378	across sites/scanners because some of the MRI scanners actually underwent inappropriate
379	installation and were set with different parameters. The results were then sent back to the
380	collaborators, who edited the parameters. We also checkrf the DICOM files that are deposited in
381	the ATR XNAT server. In this phase, we checked the parameters, slice numbers, and diffusion
382	gradient information (byec and byal).
383	The manuals were shared and used at the sites for protocol installation, demographic and
384	clinical assessment before the scan (e.g. handedness), and the assessment of and instruction to
385	participants during the scan (e.g. general instruction during the scan, fixation to the cross during

386 rsfMRI scans, and the assessment of sleepiness during the rsfMRI).

Subset	Sequence	Duration			Participant instruction
		Pris	sma	Skyra, Trio, Verio Dot, Verio	
		CRHD	HARP	HARP	
rsfMRI 1	SEF AP	0:32	0:06		Fixation
	BOLD AP	5:46	5:08		Fixation
	SEF PA	0:32	0:06		Fixation
	BOLD PA	5:46	5:08		Fixation
Structure	T1 MPR	6:38	5:22		Rest
	T2 SPC	5:57	5:31	5:22-6:26	Rest
Subtotal		25 min	22 min	22-23 min	
ASL		NA	2:45 <sup>b</sup>		Rest
QSM		NA	5:03 <sup>c</sup>		Rest
DWI	AP	6:07	3:29	4:50	Rest
	PA	6:05	3:32	4:54	Rest
	AP	5:39	NA	NA	Rest
	PA	5:39	NA	NA	Rest
rsfMRI 2	See rsfMRI 1 <sup>a</sup>	13 min	11 min		Fixation
rsfMRI 3	See rsfMRI 1 <sup>a</sup>	NA	11 min		Fixation
Task fMRI EMOTION	SEF AP	NA	0.06		Task
	SEF PA	NA	0.06		Task
	BOLD PA	NA	4.08		Task
Task fMRI CARIT	SEF AP	NA	0.06		Task
	SEF PA	NA	0.06		Task
	BOLD PA	NA	4.08		Task
Total		61 min	68 min	59-68 min	

#### 387 Table 2. CRHD and HARP protocols.

388 Abbreviations: rsfMRI, resting-state functional MRI; ASL, arterial spin labeling; QSM,

389 quantitative susceptibility mapping; DWI, diffusion weighted imaging; SEF, spin echo field

mapping; BOLD, blood oxygenation level dependent; T1 MPR, T1-weighted magnetization 390

prepared rapid acquisition with gradient echo; T2 SPC, T2-weighted sampling perfection with 391

392 application optimized contrasts using different flip angle evolutions.

393 a A set of SEF AP, BOLD AP, SEF PA, and BOLD PA.

394 b Only for Prisma and Skyra.

395 c Only for Prisma, Skyra, and Verio Dot.




Figure 3. Quality of MRI and preliminary cortical structures obtained by HARP in a single traveling subject across scanners/sites.

A) Temporal signal-to-noise ratio (tSNR) obtained in a single subject (ID = 9503) across different scanners/sites by a harmonized MRI protocol (a sequence of functional MRI in HARP using a multi-band echo planar imaging with TR/TE = 800/34.4 ms; see Supplementary Table S1 for other details). The images from top to bottom show color-coded tSNR maps in 32k greyordinates (see main text) overlaid on the lateral and medial surface of the mid-thickness surface of the left hemisphere, the subcortical sections of the T1w image, and the histogram of the tSNR values. B) Cortical myelin contrast (T1w/T2w ratio) across different scanners. The myelin contrast is corrected for the biasfield and parcellated by the HCP MMP v1.0 (Glasser et al., 2016a). C) The map shows cortical thickness across different scanners. Cortical thickness is corrected by curvature and parcellated by the HCP MMP v1.0. The tSNR, myelin map and cortical thickness are comparable across scanners. Data at <a href="https://balsa.wustl.edu/7q4P9">https://balsa.wustl.edu/7q4P9</a> and <a href="https://balsa.wustl.edu/7q4P9">https://balsa

- 396
- 397 2.3. Cognitive and behavioral assessment
- 398 Each participating site assesses demographic characteristics (i.e. age, sex, and socioeconomic
- 399 status), clinical characteristics (i.e. diagnosis, symptom severity, cognitive function, and general
- 400 functioning), and subjective social evaluations (i.e. quality of life and well-being) (Table 3).
- 401 Each subgroup (G1-1D, G1-1A, G1-1S, and G1-2 TS) indicates standard scales, some of which
- 402 are uniform across subgroups and easier to share and use when analyzing brain images.

	1, 0		
	G1-1D	G1-1A	G1-1S
Depression	K6 or BDI-II	BDI-II and PHQ-	PHQ-9 and BDI-II/GDS-
		9	15
Anxiety	—	GAD-7	STAI
Autism	AQ-10, AQ-50 or SRS-2 (for developmental disorders)	AQ-10 or AQ-50	—
Psychosis	APSS	_	NPI-Q
Intellectual ability	JART-25 or WAIS-III (WISC at the age of 15 years or less) Information and Picture completion subtests	JART-25	JART-25
Cognitive function	CANTAB or BACS-J	CANTAB or BACS-J	ADAS-Cog11, CDT, CDR, FAB, HVLT-R, JLO, MMSE, MoCA-J, SDMT, TMT-A/B, WMS- R
General function and disability	GAF, mGAF or WHO-DAS 2.0	GAF, mGAF or WHO-DAS 2.0	Schwab & England ADL
Quality of life	EQ-5D	EQ-5D	PASE
Well-being	WHO-5	WHO-5	SHAPS
Handedness	EHRS or UTokyo	EHRS or UTokyo	UTokyo

## 403 Table 3. Clinical and neuropsychological assessment.

404 Abbreviations: K6, 6-item Kessler Screening Scale for Psychological Distress; BDI-II, Beck 405 Depression Inventory – Second Edition; PHQ-9, Patient Health Questionnaire-9; GDS-15, Geriatric Depression Scale 15; GAD-7, General Anxiety Disorder-7; STAI, State-Trait Anxiety 406 407 Inventory; AQ-10, 10-item short version of the Autism Spectrum Quotient; AQ-50, Autism 408 Spectrum Quotient (original version); APSS, Adolescent Psychotic-like Symptom Screener; 409 NPI-Q, Neuro Psychiatric Inventory-Brief Questionnaire Form; JART-25, 25-item short version 410 of the Japanese Adult Reading Test; WAIS-III, Wechsler Adult Intelligence Scale-Third 411 Edition; GAF, Global Assessment of Functioning; mGAF, modified GAF; WHO-DAS 2.0, the 412 World Health Organization Disability Assessment Schedule II: Schwab & England ADL, 413 Modified Schwab and England ADL (Activities of Daily Living) scale; CANTAB, Cambridge 414 Neuropsychological Test Automated Battery; BACS-J, the Brief Assessment of Cognition in 415 Schizophrenia Japanese version; ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive 416 component; CDT, Clock Drawing Test; CDR, Clinical Dementia Rating; FAB, Frontal 417 Assessment Battery; HVLT-R, Hopkins Verbal Learning Test-Revised; JLO, Judgment of Line 418 Orientation; MMSE, Mini-Mental State Examination; MoCA-J, Japanese version of Montreal 419 Cognitive Assessment; SDMT, Symbol Digit Modality Test; TMT-A/B, Trail Making Test Parts A and B; WMS-R, Wechsler Memory Scale-Revised; EQ-5D, EuroQol 5 Dimension 420 questionnaire; WHO-5, World Health Organization-Five Well-Being Index; PACE, Physical 421 422 Activity Scale for Elderly; SHAPS, Snaith-Hamilton Pleasure Scale; EHI, Edinburgh 423 Handedness Inventory; UTokyo, 14-item Rating Scale of Handedness for Biological Psychiatry 424 Research among Japanese People.


## 425 2.4. Travelling subject project

Based on the previous study (Yamashita et al., 2019), we also conducted a TS project for the
CRHD and HARP protocols. In some sites, we also use the former protocols to combine with
existing large-scale datasets (Iwatsubo et al., 2018; Okada et al., 2016; Yahata et al., 2016;
Yamashita et al., 2019). Because we limit the scanners, head coils, and protocols in this project,
we expect to see reduced measurement biases, which may enhance the disease-related effect size
in clinical studies and provide better ways to diminish bias in future studies.

432 The previous data harmonization using the TS dataset was based on a GLM (Yamashita 433 et al., 2019); however, the present TS project may provide a harmonization method using a 434 general linear mixed model (GLMM; Figure 1), given that the new protocols require a longer 435 scan time compared to previous protocols ( $\sim 20 \text{ min for T1w}$  imaging and rsfMRI). To ensure the 436 images from all sites are well harmonized, we applied a hub-and-spoke model to arrange 437 traveling scans at each recruitment site (Supplementary Table S2). Each participant undergoes 438 CRHD and HARP scans using the Prisma (~2 hours) at one or more hub sites (UTK, UTI, and 439 ATR) to harmonize the data within the Brain/MINDS Beyond project and other projects (e.g. Brain/MINDS, HCP, and ABCD) and test the difference in quality between the protocols. The 440 441 other visiting sites were determined in consideration of the site locations, machine differences, 442 and project similarities between the sites. Each participant receives multiple scans at the 443 recruitment site to assess the test-retest reliability (1 hour x 2 sessions). The interval between 444 scans may vary by site due to scanner time restrictions but we aim to determine whether the gap 445 between test-retest scans would be associated with reliability.

446 For the TS project, 75 healthy adults—five or more participants per site—are scheduled
447 to undergo 6 to 8 scans at three or more sites within 6 months (Supplementary Table S2). The

- total number of scans and spokes between the sites are expected to be 455 and 465, respectively
- 449 (Figure 4A). As of March 2020, 74 participants were registered and 405 scans (89.0 %) were
- 450 completed and uploaded to the ATR XNAT server. The data provided 368 spokes (76.1 %,
- 451 Figure 4B). The TS project will end in August 2020.
- We also plan another TS project including task fMRI sequences in HARP to see the
  validity and reliability of the task fMRI paradigms and the applicability of harmonizing higher
  quality registration using the task fMRI data. The task fMRI TS study is set to begin September
  2020 and will include 10 participants, 4 sites (UTK [including test-retest], UTI, TMG and SWA),
  and a total of 50 scans.



# Figure 4. Expected and current data connection of the traveling subjects.

Data connections in the traveling subject project that were (A) initially planned and (B) the actual connections as of March 2020. Hub sites using Prisma and other sites using Prisma, Skyra, Trio A Tim, Verio Dot, and Verio are illustrated in red, orange, blue, green, purple, and pink, respectively.

457

458 2.5. Data storage, preprocessing, and quality control

## 459 *2.5.1. Data logistics*

Brain MR images obtained using the CRHD and HARP protocols in this study project and 460 461 related studies are stored, preprocessed, and distributed using the XNAT server system 462 (https://www.xnat.org/) (Figure 5). Due to the legacy of previous multi-site studies (Iwatsubo et 463 al., 2018; Yahata et al., 2016; Yamashita et al., 2019), several data centers were already available 464 for this project. The images obtained from the development and adult projects (G1-1D and G1-465 1A) will be sent to an XNAT server at ATR and the clinical data will be sent to UTI. For the 466 senescent project (G1-1S), all the data will be sent to the NCNP (Iwatsubo et al., 2018). The TS 467 data will also be sent to the ATR server shown in dashed lines. When uploading to the XNAT 468 server, personal information (i.e. name and date of birth) contained in DICOM is automatically 469 removed using an anonymization script of XNAT. A defacing procedure is performed for T1w 470 and T2w images. These processes de-identify the MRI data. After manually checking whether 471 the face images are completely obscured, all the anonymized MRI data are shared using Amazon 472 AWS with RIKEN BDR, in which all image preprocessing is performed (See Preprocessing 473 pipelines section). Preprocessed data are sent back to the servers and can be seen with limited access (i.e. participating sites). After a quality control (QC), cleaned imaging data with a 474 475 demographic and clinical datasheet will be stored in the distribution server(s). All data will be 476 also sent to backup server(s).




Figure 5. Data storage, preprocessing, quality check, and data sharing.


MRI (black line) and clinical (blue line) data from G1-1D and G1-1A sites are sent to the XNAT server and a data server at ATR and UTI, respectively. All data from G1-1S sites are sent to an XNAT server and a data server managed by NCNP, as this group applied a standard clinical assessment protocol to the project following a previous multi-site study. Traveling subject data from G1-1S sites are also sent to the XNAT server in ATR (dot line). XNAT servers at NCNP, ATR, and RIKEN BDR are linked by Amazon AWS to share the imaging data. NCNP manages a separate server for storing clinical data (Clin DB) being collected from the participants in this project. All MR images are preprocessed at RIKEN BDR. All of the raw and preprocessed data will be stored and provided to the users in a distribution server. A backup server will be placed at a different site.

- 477
- 478 2.5.2. Preprocessing pipelines
- 479 All neuroimaging data are preprocessed at RIKEN BDR for this project. The MR images are sent
- 480 via Amazon S3 to a high-throughput parallel computing system at RIKEN BDR for
- 481 preprocessing. The preprocessing is performed using the HCP pipeline 4.2.0 (Glasser et al.,
- 482 2013) with modifications for adapting and harmonizing multiple scanners. In brief, the structural
- 483 MRI (T1w and T2w) is first corrected for image distortions related to the gradient nonlinearity in
- 484 each scanner type and the inhomogeneity of the B0 static magnetic field in each scan. The signal

485 homogeneity is dealt with by prescan normalization and is also improved by a biasfield 486 correction using T1w and T2w images (Glasser and Van Essen, 2011). The T1w and T2w 487 images are fed into non-linear registration to the Montreal Neurological Institute (MNI) space 488 and used for cortical surface reconstruction using FreeSurfer (Fischl, 2012), surface registration 489 using multi-modal surface matching (MSM) (Robinson et al., 2018) and folding pattern 490 (MSMsulc); this is followed by the creation of a myelin map using T1w divided by T2w and 491 surface mapping (Glasser and Van Essen, 2011). An example of a cortical myelin map in a single 492 subject (ID = 9503) across scanners/sites is parcellated by HCP MMP v1.0 (Glasser et al., 2016a) 493 and presented in Figure 3B, revealing the typical cortical distribution of the high myelin contrast 494 in the primary sensorimotor (aeras 1, 3a, 3b, 4), auditory (A1), visual (V1), middle temporal, and 495 ventral prefrontal (47m) areas—as demonstrated previously (Glasser and Van Essen, 2011), and 496 is quite comparable between scanners.

497 The functional MRI data is corrected for distortion (gradient nonlinearity and B0-498 inhomogeneity) and motion. The distortion from B0 static field inhomogeneity is corrected by 499 means of opposite phase encoding spin echo fieldmap data using TOPUP (Andersson et al., 500 2003); it is then warped and resampled to MNI space at a 2 mm resolution and saved as a volume 501 in the Neuroimaging Informatics Technology Initiative (NIFTI) format. The region of the 502 cortical ribbon in the fMRI volume is further mapped onto the cortical surface and combined 503 with voxels in the subcortical gray region to create 32k greyordinates in the Connectivity 504 Informatics Technology Initiative (CIFTI) format. Multiple runs of the fMRI data are merged 505 and fed into independent component analyses (ICA) followed by an automated classification of 506 noise components and the removal of noise components using FIX (Salimi-Khorshidi et al., 507 2014) (Glasser et al., 2018). The automated classifier is trained using the data in this project and

508	its accuracy is maximized. The denoised fMRI data, in combination with other cortical metrics
509	(myelin, thickness; Figure 3B and 3C, respectively), is further used for multi-modal registrations
510	(MSMAll) over the cortical surface, followed by 'de-drifting' (removing registration bias after
511	multimodal registration) based on the group sampled in this study (Glasser et al., 2016a). The
512	resting-state seed-based functional connectivity in an example of a single subject (ID = 9503)
513	revealed a typical pattern over the cerebral cortex across scanners/sites; the left frontal eye field
514	(FEF)-seed functional connectivity showed symmetric coactivation in the bilateral premotor eye
515	field (PEF) (Figure 6A), whereas the left area 55b-seed FC showed an asymmetric language
516	network distributed in the peri-sylvian language (PSL) area, superior temporal sulcus (STS), and
517	areas 44/45 predominantly in the left hemisphere (Figure 6B).
518	The diffusion MRI is corrected for distortion and motion due to gradient nonlinearity,
518 519	The diffusion MRI is corrected for distortion and motion due to gradient nonlinearity, eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and
519	eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and
519 520	eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and Sotiropoulos, 2016). The signal dropouts, susceptibility artefact, and their interaction with
519 520 521	eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and Sotiropoulos, 2016). The signal dropouts, susceptibility artefact, and their interaction with motion were also corrected (Andersson et al., 2018; Andersson et al., 2017). The resulting
519 520 521 522	eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and Sotiropoulos, 2016). The signal dropouts, susceptibility artefact, and their interaction with motion were also corrected (Andersson et al., 2018; Andersson et al., 2017). The resulting diffusion volumes are merged into a single volume and resampled in the subject's real physical
519 520 521 522 523	eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and Sotiropoulos, 2016). The signal dropouts, susceptibility artefact, and their interaction with motion were also corrected (Andersson et al., 2018; Andersson et al., 2017). The resulting diffusion volumes are merged into a single volume and resampled in the subject's real physical space aligned according to the ACPC convention. Diffusion modeling is performed using nerite
519 520 521 522 523 524	eddy current, motion, and B0 static field inhomogeneity using EDDY (Andersson and Sotiropoulos, 2016). The signal dropouts, susceptibility artefact, and their interaction with motion were also corrected (Andersson et al., 2018; Andersson et al., 2017). The resulting diffusion volumes are merged into a single volume and resampled in the subject's real physical space aligned according to the ACPC convention. Diffusion modeling is performed using nerite orientation density imaging (NODDI) (Fukutomi et al., 2018; Zhang et al., 2012), and a Bayesian




# Figure 6. Seed-based resting-state functional connectivity in a single traveling subject across scanners/sites

In a single subject (ID = 9503), the resting-state fMRI scans (5 min x 4) were collected using a scanning protocol of HARP across different scanners/sites (see Supplementary Table S1), preprocessed, and denoised by a surface-based analysis to generate parcellated functional connectivity (FC) using the HCP MMP v1.0 (Glasser et al., 2016a). A) FC seeded from the left frontal eye field (FEF), which was distributed symmetrically in the bilateral premotor eye field (PEF) and comparable across scanners/sites. B) FC seeded from the left area 55b, which showed an asymmetric language network predominant in the left hemisphere that was comparable across scanners/sites. The language network is distributed in the areas of 44/45, superior temporal sulcus, dorsal posterior part (STSdp), and peri-sylvian language (PSL). Data at https://balsa.wustl.edu/1B9VG and https://balsa.wustl.edu/5Xr71

## 528

# 529 2.5.3 Preliminary travelling subject data

Here, we show the preliminary results obtained from the initial TS data (as detailed in section 530 531 2.4). In the initial TS study, five healthy subjects participated and travelled across five sites and received MRI scanning with HARP in different scanners, and four of them completed all the 532 travelling scans as planned. Datasets were analyzed with the current version of preprocessing 533 534 (see section 2.5.2) and each of the cortical thickness, myelin, and resting-state functional 535 connectivity was parcellated using HCP MMP v1.0 (Glasser et al., 2016a) as described above (a 536 part of the parcellated data in an exemplar subject [ID = 9503] was already shown in Figure 3 and 6). To investigate similarity of the data, each of the parcellated metrics was fed into an 537 analysis of Spearman's rank correlation across subjects and sites/scanners. Figure 7 shows the 538 resultant similarity matrices which demonstrate higher correlation coefficients of within-subjects 539 540 than those of cross-subjects in all the metrics of cortical thickness, myelin, and functional connectivity. These findings suggest that our approach with harmonized protocols and 541 preprocessing is promising for capturing a subject-specific imaging biomarker. 542



# Figure 7. Similarity of the cortical metrics across subjects and sites/scanners in preliminary travelling subject study

From left to right show the correlation matrices of the parcellated cortical thickness, myelin and functional connectivity in four travelling subjects (TS). Number of parcellated metrics

used for analysis were 360 for thickness and myelin and 129,240 for functional connectivity, which cover all the cerebral cortex in both hemispheres. The correlation coefficient of Spearman's rho is presented by a color bar placed at the bottom.

543

## 544 2.5.4. Quality control

QC is implemented in several stages: 1) a brief image check during each scan; 2) an anomaly and 545 546 abnormality inspection by the radiologists; 3) an assessment of raw data image quality when 547 uploading data to the XNAT server; and 4) preprocessed image quality checks. QC 1 is 548 conducted by site personnel and the participants are rescanned within the same session if scan time remains, if the images have major artifacts, such as those due to head movement. QC 2 is 549 550 conducted by radiologists at the measurement site or other sites if any radiologist at the site is 551 unable to check the images. QC 3 is manually conducted by researchers at the measurement sites 552 before uploading the data to a server for all images in reference to the HCP OC manual (Marcus 553 et al., 2013). After uploading the images to the XNAT servers, all images are first checked 554 according to the DICOM file information as to whether the images are correctly updated. The 555 researchers at each site are informed of missing DICOM files and any irregular parameters 556 detected in the DICOM files. In QC 3, the T1w and T2w images are manually checked as to 557 whether the face images are completely removed. Then, signal distributions of the myelin map 558 are checked for outliers because of its sensitivity to several artifacts and errors such as motion, 559 reconstruction of the images, and cortical surface reconstruction. Functional and diffusion 560 images are automatically checked for outliers, and the images and data will be checked by visual inspection. In the QC 3 process, a QC pipeline will be implemented for checking the images 561 562 (Marcus et al., 2013). QC 4 uses preprocessed CIFTI images that will be checked in several preprocessing steps. Any irregular scans and remarks are recorded in the clinical data servers and 563 564 the information will be used when determining the eligibility criteria for each study.

565

## 566 2.6. Ethical regulation

567 Sharing neuropsychiatric patient data, which may contain information linked to subjects' 568 privacy, requires special attention (Sadato et al., 2019). Therefore, the Brain/MINDS Beyond 569 project put NCNP as the core site for supporting ethical considerations. Before participating in 570 the project, all institutions are required to receive approval from their ethical review board 571 regarding their research plans. This includes the following points and ethical documentation: 1) 572 MR images and clinical data of the participants may be shared within the Brain/MINDS Beyond 573 project or Japanese/International scientific institutions for collaboration. De-identified MR images with limited clinical data (see below) may become publicly accessible on an open 574 575 database for research purposes. 2) MR images of the participants may be compared with non-576 human primate MRI data. 3) Intellectual property rights originating from the research of the 577 Brain/MINDS Beyond project shall be attributed to the institutes of the researchers and not the 578 participants. All participants must provide written informed consent to participate in this project 579 after receiving a complete explanation of the experiment.

The Japanese regulations for the sharing of personal information used for research
purposes requires attention in dealing with two types of data: "individual identification codes"
and "special care-required personal information"

583 (<u>http://www.japaneselawtranslation.go.jp/law/detail/?id=2781&vm=04&re=01</u>). Individual

identification codes are direct identifiers—information sufficient to identify a specific individual.

585 Special care-required personal information represents indirect identifiers needing special care in

handling so as not to cause potential disadvantages to participants. In consideration of these

regulations, data accompanied with the MR images are limited in the publicly accessible open

database, and only include 5-year age bins, sex, diagnostic information, handedness, simple
socioeconomic status, clinical scale scores, and sleepiness scale scores. In the Brain/MINDS
Beyond project, we exclude the datasets of MR images containing facial information from the
data in the publicly accessible open database.

592

593 2.7. Data sharing

In the current provisional plan of sharing the collected data, we have designated three types ofdata sharing:

596 1) Access via an open database: de-identified MR images and limited clinical data are to become
597 publicly accessible for research purposes after the research period ends. The initial release will

598 be scheduled in 2024. Basic demographic and clinical characteristics such as 5-year age bin, sex,

599 socioeconomic status, (premorbid) estimated intellectual quotient, main diagnosis, representative

scale scores for each disease and sleepiness during rsfMRI scan will be shared.

2) Application-based sharing: MR images and the clinical datasets are shared after receiving

application approval for data usage by the Brain/MINDS Beyond human brain MRI study

603 working group. Applicants are required to obtain approval of their research plan from the ethical

604 review board of their institution and request the dataset type in the application form. The

605 working group discusses the eligibility of the applicants, as well as the availability of the

requested dataset, the ethical consideration in the Brain/MINDS Beyond site(s), and any conflict

from other applications. Data is released from the distribution server of the Brain/MINDS

608 Beyond project with limited access.

609 3) Collaboration-based sharing: This form of sharing is used for individual collaborative studies.

610 A research proposal collaborating with the institute(s) in the Brain/MINDS Beyond project is

- 611 approved by the ethical review board of the institute(s). Data is shared from the relevant
- 612 institute(s).

#### 613 **3. Discussion**

614 The Brain/MINDS Beyond human brain MRI study expands upon research from previous multi-615 site neuroimaging studies in Japan and provides high quality brain images by standardizing 616 multiple MRI scanners and protocols. An unbiased and quantitative assessment of cortical 617 structure and function may be needed for sensitive and specific predictions of any dynamics, 618 perturbations, or disorders of the brain system. Multi-modal cross-disease image datasets are 619 systematically and properly acquired, analyzed, and shared to enable investigation of common 620 and disease-specific features for psychiatric and neurological disorders with a high sensitivity 621 and specificity. A distinct feature of this project is to include a study design with the TS project, 622 which enables harmonizing the multi-site data from lower (i.e. preprocessing) to higher levels 623 (i.e. statistics). The harmonization protocols are available at http://mriportal.umin.jp. The 624 Brain/MINDS Beyond human brain MRI project can provide brain imaging biomarkers that are 625 applicable to therapeutic targets and diagnostic supports.

626 To date, several national projects have applied high-quality multimodal MRI protocols, in 627 addition to a preprocessing pipeline, to a large cohort (e.g., HCP, UK biobank, and ABCD). 628 Unlike these multi-site projects, we plan to investigate brain organization associated with brain 629 disorders that occur throughout the lifespan and to develop imaging biomarkers that can be 630 implemented in clinical trials. To facilitate the collection of a larger number of patients with 631 different brain disorders, multiple clinical research sites are participating in this project and 632 cooperating for standardized data acquisitions. The core of the project began from establishing a 633 standardized protocol (i.e. HARP) based on five 3T MRI scanners, but it will continue to develop 634 a comparable protocol for other types of scanners/vendors. The protocol is designed not only for 635 high-resolution structural MRI and high-quality resting-state fMRI, but also for diffusion MRI

37

636 and other imaging—including scans for correcting distortions. The preprocessing is performed 637 with a surface-based multi-modal analysis to minimize bias largely generated from the variability 638 in cortical folding across subjects (Coalson et al., 2018; Glasser et al., 2016b). The preliminary 639 data demonstrated high quality MRI images and the fidelity of structural and functional brain 640 organizations across scanners/sites. The signal-to-noise ratio of MRI images was very high 641 across scanners/sites (Figure 3A). The cortical metrics of structure (myelin map, thickness) 642 (Figure 3B-C) were comparable to those previously reported in the literature (Fischl and Dale, 643 2000; Glasser and Van Essen, 2011), as well as the functional connectivity related to eye 644 movements involving FEF and PEF (Figure 6A) (Amiez and Petrides, 2009) and a language network involving left 55b, 44/45, STS, and PSL (Figure 6B) (Glasser et al., 2016a). These 645 646 findings suggest that a surface-based parcellated analysis may provide useful and reliable metrics 647 concerning cortical structure, function, and connectivity, and may potentially contribute to the 648 establishment of multi-modal imaging biomarkers of brain disorders. The initial trial with four 649 TS also demonstrated sensitivity to the subject-specific features across scanners/sites (Figure 7), 650 suggesting the reliability of our harmonizing protocols and preprocessing.

651 The TS approach is a novel harmonization method for multi-site brain image data 652 (Yamashita et al., 2019), which has proven that measurement bias from MRI equipment and 653 protocols can be differentiated from sampling bias between sites. Instead of using a previously 654 applied GLM, we plan to expand the statistical approach to a GLMM in this project. One of the 655 obstacles of the GLMM approach is that it requires a larger number of total scans compared to 656 those in a GLM approach; overlapping scans at hub sites are required for all TS participants to 657 ensure the data connectivity; additionally, a larger number of TS participants is required in the 658 TS project because the degree of freedom can be reduced in the GLMM. However, one of the

659 benefits of the GLMM approach includes that it is flexible with the variability in data 660 acquisition—such as the number of scans per participant and length of scan time per protocol; 661 thus, is suitable for a big project. Furthermore, this approach allows the addition of another site, 662 scanner, and protocol to an existing TS network, which can deal with the future upgrades of 663 scanners and protocols. In fact, the scanners at two sites (UHI and SWA) were upgraded to a 664 MAGNETOM Skyra fit (Siemens Healthcare GmbH, Erlangen, Germany) for institutional 665 reasons after the Brain/MINDS Beyond project had started. Therefore, we customized the TS for 666 two sites to ensure that the data are properly connected before and after the upgrades. Also, the 667 project welcomes other sites to participate in the TS network.

Because this project focuses on various brain disorders across the lifespan, we aim to 668 669 identify common and disease-specific features of psychiatric and neurological disorders. While 670 some case-control studies suggest possible neural mechanisms in a psychiatric disease, other 671 studies suggest that the effects may not be specific to a single entity but instead may be shared 672 across multiple neuropsychiatric disorders (Hibar et al., 2018; Schmaal et al., 2017; Schmaal et 673 al., 2016; van Erp et al., 2016). Such non-specificity may be at least partly addressed by 674 investigating diseases across the lifespan, since some of brain changes reported in psychiatric 675 disorders also occur in aging or development in healthy subjects, e.g. volumetric changes in 676 subcortical structures in schizophrenia (Okada et al., 2016; van Erp et al., 2016) and in healthy 677 aging (O'Shea et al., 2016; Wang et al., 2019). We initially coordinated with 13 sites to explore 678 various psychiatric and neurological disorders throughout the lifespan and to make use of a 679 powerful harmonization method. Therefore, this project aims to identify both the common and 680 disease-specific pathophysiology features of psychiatric and neurological disorders, which will

39

hopefully lead to imaging biomarkers for general clinical practice and the development ofcandidate therapeutic targets for future clinical trials.

683 In conclusion, the Brain/MINDS Beyond human brain MRI project began with the 684 participation of 13 clinical research sites—all of which have setup brain image scans using the 685 standard MRI scanners and protocols, conducted TS scans, and will share acquired data with the 686 project and the public in the future, and commit to the analysis and publication of the data. To 687 the best of our knowledge, this is the first human brain MRI project to explore psychiatric and 688 neurological disorders across the lifespan. The project aims to discover robust findings which 689 may be directly related to the common or disease-specific pathophysiology features of such 690 diseases and facilitate the development of candidate biomarkers for clinical application and drug 691 discovery.

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.05.076273. this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.

#### 692 Acknowledgment

- 693 This research was supported by the Agency for Medical Research and Development (AMED)
- 694 under Grant Numbers JP20dm0307001 (K.K.), JP20dm0307002 (Y.O.), JP20dm0307003
- 695 (T.Han.), JP20dm0307004 (K.K.), JP20dm0307008 (M.K.), JP20dm`0307020 (N.S.),
- 696 JP20dm0207069 (S.K.) and JP20dm0307006 (T.Hay.). This study was also supported by the
- 697 University of Tokyo Center for Integrative Science of Human Behaviour (CiSHuB) and the
- 698 International Research Center for Neurointelligence (WPI-IRCN) at the University of Tokyo
- 699 Institutes for Advanced Study (UTIAS).
- 700

# 701 <u>Author Contributions</u>

- 702 Shinsuke Koike, Conceptualization, Project administration, Funding acquisition, Writing –
- 703 original draft, Software, Resources;
- 704 Saori C Tanaka, Conceptualization, Project administration, Data Curation, Software, Resources,
- 705 Writing original draft;
- 706 Tomohisa Okada, Methodology, Investigation;
- 707 Toshihiko Aso, Investigation, Formal Analysis, Validation;
- 708 Michiko Asano, Investigation, Data curation;
- 709 Norihide Maikusa, Methodology, Resources;
- 710 Kentaro Morita, Writing original draft;
- 711 Naohiro Okada, Investigation, Writing original draft;
- 712 Masaki Fukunaga, Methodology;
- 713 Akiko Uematsu, Methodology, Investigation;
- 714 Hiroki Togo, Methodology, Investigation;

- 715 Atsushi Miyazaki, Methodology, Investigation;
- 716 Katsutoshi Murata, Methodology;
- 717 Yuta Urushibata, Methodology;
- 718 Joonas Autio, Methodology;
- 719 Takayuki Ose, Methodology;
- 720 Junichiro Yoshimoto, Methodology;
- 721 Toshiyuki Araki, Writing original draft;
- 722 Matthew F Glasser, Software, Writing reviewing and editing;
- 723 David C Van Essen, Writing reviewing and editing;
- 724 Megumi Maruyma, Project administration;
- 725 Norihiro Sadato, Investigation, Funding acquisition, Project administration;
- 726 Mitsuo Kawato, Conceptualization, Funding acquisition, Project administration;
- 727 Kiyoto Kasai, Investigation, Funding acquisition, Project administration, Supervision;
- 728 Yasumasa Okamoto, Investigation, Funding acquisition;
- 729 Takashi Hanakawa, Project administration, Funding Acquisition, Methodology, Investigation,
- 730 Resources, Writing original draft;
- 731 Takuya Hayashi, Conceptualization, Project administration, Funding Acquisition, Software,
- 732 Resources, Formal Analysis, Writing original draft, reviewing and editing.
- 733

### 734 Conflict of interest

- 735 Katsutoshi Murata and Yuta Urushibara are employed by Siemens Healthcare K.K., Tokyo,
- 736 Japan. The other authors report no financial relationships with commercial interests.
- 737

## 738 Data availability

- 739 The data presented in Figure 3 and 6 are available at BALSA
- 740 (<u>https://balsa.wustl.edu/study/show/npD26</u>). Harmonization protocols and other information of the
- 741 project are available at the BrainMINDS beyond MRI portal site
- 742 (<u>http://mriportal.umin.jp/?lang=en</u>). See also Data sharing section in details of data obtained in
- future in this project. For proposal and requests for the data usage, please contact to Saori Tanaka
- 744 (<u>xsaori@atr.jp</u>).

### 745 **<u>References</u>**

- Amiez, C., Petrides, M., 2009. Anatomical organization of the eye fields in the human and non-human
   primate frontal cortex. Prog Neurobiol 89, 220-230.
- Andersson, J.L., Skare, S., Ashburner, J., 2003. How to correct susceptibility distortions in spin-echo
   echo-planar images: application to diffusion tensor imaging. Neuroimage 20, 870-888.
- Andersson, J.L.R., Graham, M.S., Drobnjak, I., Zhang, H., Campbell, J., 2018. Susceptibility-induced
  distortion that varies due to motion: Correction in diffusion MR without acquiring additional data.
  Neuroimage 171, 277-295.
- Andersson, J.L.R., Graham, M.S., Drobnjak, I., Zhang, H., Filippini, N., Bastiani, M., 2017. Towards a
   comprehensive framework for movement and distortion correction of diffusion MR images: Within
   volume movement. Neuroimage 152, 450-466.
- Andersson, J.L.R., Sotiropoulos, S.N., 2016. An integrated approach to correction for off-resonance
   effects and subject movement in diffusion MR imaging. Neuroimage 125, 1063-1078.
- Ando, S., Nishida, A., Yamasaki, S., Koike, S., Morimoto, Y., Hoshino, A., Kanata, S., Fujikawa, S.,
  Endo, K., Usami, S., Furukawa, T.A., Hiraiwa-Hasegawa, M., Kasai, K., Scientific, T.T.C., Data
  Collection, T., 2019. Cohort Profile: The Tokyo Teen Cohort study (TTC). Int J Epidemiol 48, 14141414g.
- Beheshti, I., Maikusa, N., Daneshmand, M., Matsuda, H., Demirel, H., Anbarjafari, G., JapaneseAlzheimer's Disease Neuroimaging, I., 2017. Classification of Alzheimer's Disease and Prediction of
  Mild Cognitive Impairment Conversion Using Histogram-Based Analysis of Patient-Specific
  Anatomical Brain Connectivity Networks. J Alzheimers Dis 60, 295-304.
- Behrens, T.E., Woolrich, M.W., Jenkinson, M., Johansen-Berg, H., Nunes, R.G., Clare, S., Matthews,
  P.M., Brady, J.M., Smith, S.M., 2003. Characterization and propagation of uncertainty in diffusionweighted MR imaging. Magn Reson Med 50, 1077-1088.
- Bookheimer, S.Y., Salat, D.H., Terpstra, M., Ances, B.M., Barch, D.M., Buckner, R.L., Burgess, G.C.,
  Curtiss, S.W., Diaz-Santos, M., Elam, J.S., Fischl, B., Greve, D.N., Hagy, H.A., Harms, M.P., Hatch,
  O.M., Hedden, T., Hodge, C., Japardi, K.C., Kuhn, T.P., Ly, T.K., Smith, S.M., Somerville, L.H.,
  Ugurbil, K., van der Kouwe, A., Van Essen, D., Woods, R.P., Yacoub, E., 2019. The Lifespan Human
  Connectome Project in Aging: An overview. Neuroimage 185, 335-348.
- Casey, B.J., Cannonier, T., Conley, M.I., Cohen, A.O., Barch, D.M., Heitzeg, M.M., Soules, M.E.,
  Teslovich, T., Dellarco, D.V., Garavan, H., Orr, C.A., Wager, T.D., Banich, M.T., Speer, N.K.,
  Sutherland, M.T., Riedel, M.C., Dick, A.S., Bjork, J.M., Thomas, K.M., Chaarani, B., Mejia, M.H.,
  Hagler, D.J., Jr., Daniela Cornejo, M., Sicat, C.S., Harms, M.P., Dosenbach, N.U.F., Rosenberg, M.,
  Earl, E., Bartsch, H., Watts, R., Polimeni, J.R., Kuperman, J.M., Fair, D.A., Dale, A.M., Workgroup,
- A.I.A., 2018. The Adolescent Brain Cognitive Development (ABCD) study: Imaging acquisition
  across 21 sites. Dev Cogn Neurosci 32, 43-54.
- Coalson, T.S., Van Essen, D.C., Glasser, M.F., 2018. The impact of traditional neuroimaging methods on
   the spatial localization of cortical areas. Proc Natl Acad Sci U S A 115, E6356-E6365.
- Degenhardt, L., Chiu, W.T., Sampson, N., Kessler, R.C., Anthony, J.C., Angermeyer, M., Bruffaerts, R.,
  de Girolamo, G., Gureje, O., Huang, Y., Karam, A., Kostyuchenko, S., Lepine, J.P., Mora, M.E.,
  Neumark, Y., Ormel, J.H., Pinto-Meza, A., Posada-Villa, J., Stein, D.J., Takeshima, T., Wells, J.E.,
  2008. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO
  World Mental Health Surveys. PLoS Med 5, e141.
- Donahue, C.J., Sotiropoulos, S.N., Jbabdi, S., Hernandez-Fernandez, M., Behrens, T.E., Dyrby, T.B.,
  Coalson, T., Kennedy, H., Knoblauch, K., Van Essen, D.C., Glasser, M.F., 2016. Using Diffusion
  Tractography to Predict Cortical Connection Strength and Distance: A Quantitative Comparison with
  Tracers in the Monkey. J Neurosci 36, 6758-6770.
- 792 Drysdale, A.T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R.N., Zebley, B.,
- 793 Oathes, D.J., Etkin, A., Schatzberg, A.F., Sudheimer, K., Keller, J., Mayberg, H.S., Gunning, F.M.,
- Alexopoulos, G.S., Fox, M.D., Pascual-Leone, A., Voss, H.U., Casey, B.J., Dubin, M.J., Liston, C.,

- Filiott, L.T., Sharp, K., Alfaro-Almagro, F., Shi, S., Miller, K.L., Douaud, G., Marchini, J., Smith, S.M.,
  2018a. Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature 562,
  210-216.
- Elliott, M.L., Romer, A., Knodt, A.R., Hariri, A.R., 2018b. A Connectome-wide Functional Signature of
   Transdiagnostic Risk for Mental Illness. Biol Psychiatry 84, 452-459.
- 802 Fischl, B., 2012. FreeSurfer. Neuroimage 62, 774-781.
- Fischl, B., Dale, A.M., 2000. Measuring the thickness of the human cerebral cortex from magnetic
  resonance images. Proc Natl Acad Sci U S A 97, 11050-11055.
- Fortin, J.P., Cullen, N., Sheline, Y.I., Taylor, W.D., Aselcioglu, I., Cook, P.A., Adams, P., Cooper, C.,
  Fava, M., McGrath, P.J., McInnis, M., Phillips, M.L., Trivedi, M.H., Weissman, M.M., Shinohara,
  R.T., 2018. Harmonization of cortical thickness measurements across scanners and sites. Neuroimage
  167, 104-120.
- Fortin, J.P., Parker, D., Tunc, B., Watanabe, T., Elliott, M.A., Ruparel, K., Roalf, D.R., Satterthwaite,
  T.D., Gur, R.C., Gur, R.E., Schultz, R.T., Verma, R., Shinohara, R.T., 2017. Harmonization of multisite diffusion tensor imaging data. Neuroimage 161, 149-170.
- Fukutomi, H., Glasser, M.F., Zhang, H., Autio, J.A., Coalson, T.S., Okada, T., Togashi, K., Van Essen,
  D.C., Hayashi, T., 2018. Neurite imaging reveals microstructural variations in human cerebral cortical
  gray matter. Neuroimage 182, 488-499.
- Glasser, M.F., Coalson, T.S., Robinson, E.C., Hacker, C.D., Harwell, J., Yacoub, E., Ugurbil, K.,
  Andersson, J., Beckmann, C.F., Jenkinson, M., Smith, S.M., Van Essen, D.C., 2016a. A multi-modal
  parcellation of human cerebral cortex. Nature 536, 171-178.
- Glasser, M.F., Smith, S.M., Marcus, D.S., Andersson, J.L., Auerbach, E.J., Behrens, T.E., Coalson, T.S.,
  Harms, M.P., Jenkinson, M., Moeller, S., Robinson, E.C., Sotiropoulos, S.N., Xu, J., Yacoub, E.,
  Ugurbil, K., Van Essen, D.C., 2016b. The Human Connectome Project's neuroimaging approach. Nat
  Neurosci 19, 1175-1187.
- Glasser, M.F., Sotiropoulos, S.N., Wilson, J.A., Coalson, T.S., Fischl, B., Andersson, J.L., Xu, J., Jbabdi,
  S., Webster, M., Polimeni, J.R., Van Essen, D.C., Jenkinson, M., Consortium, W.U.-M.H., 2013. The
  minimal preprocessing pipelines for the Human Connectome Project. Neuroimage 80, 105-124.
- Glasser, M.F., Van Essen, D.C., 2011. Mapping human cortical areas in vivo based on myelin content as
  revealed by T1- and T2-weighted MRI. J Neurosci 31, 11597-11616.
- Harms, M.P., Somerville, L.H., Ances, B.M., Andersson, J., Barch, D.M., Bastiani, M., Bookheimer,
  S.Y., Brown, T.B., Buckner, R.L., Burgess, G.C., Coalson, T.S., Chappell, M.A., Dapretto, M.,
- Douaud, G., Fischl, B., Glasser, M.F., Greve, D.N., Hodge, C., Jamison, K.W., Jbabdi, S., Kandala, S.,
- Li, X., Mair, R.W., Mangia, S., Marcus, D., Mascali, D., Moeller, S., Nichols, T.E., Robinson, E.C.,
- 831 Salat, D.H., Smith, S.M., Sotiropoulos, S.N., Terpstra, M., Thomas, K.M., Tisdall, M.D., Ugurbil, K.,
- van der Kouwe, A., Woods, R.P., Zollei, L., Van Essen, D.C., Yacoub, E., 2018. Extending the
  Human Connectome Project across ages: Imaging protocols for the Lifespan Development and Aging
  projects. Neuroimage 183, 972-984.
- Hibar, D.P., Westlye, L.T., Doan, N.T., Jahanshad, N., Cheung, J.W., Ching, C.R.K., Versace, A.,
- Bilderbeck, A.C., Uhlmann, A., Mwangi, B., Kramer, B., Overs, B., Hartberg, C.B., Abe, C., Dima,
- 837 D., Grotegerd, D., Sprooten, E., Boen, E., Jimenez, E., Howells, F.M., Delvecchio, G., Temmingh, H.,
- 838 Starke, J., Almeida, J.R.C., Goikolea, J.M., Houenou, J., Beard, L.M., Rauer, L., Abramovic, L.,
- Bonnin, M., Ponteduro, M.F., Keil, M., Rive, M.M., Yao, N., Yalin, N., Najt, P., Rosa, P.G., Redlich,
- 840 R., Trost, S., Hagenaars, S., Fears, S.C., Alonso-Lana, S., van Erp, T.G.M., Nickson, T., Chaim-
- 841 Avancini, T.M., Meier, T.B., Elvsashagen, T., Haukvik, U.K., Lee, W.H., Schene, A.H., Lloyd, A.J.,
- Young, A.H., Nugent, A., Dale, A.M., Pfennig, A., McIntosh, A.M., Lafer, B., Baune, B.T., Ekman,
- 843 C.J., Zarate, C.A., Bearden, C.E., Henry, C., Simhandl, C., McDonald, C., Bourne, C., Stein, D.J.,
- 844 Wolf, D.H., Cannon, D.M., Glahn, D.C., Veltman, D.J., Pomarol-Clotet, E., Vieta, E., Canales-
- 845 Rodriguez, E.J., Nery, F.G., Duran, F.L.S., Busatto, G.F., Roberts, G., Pearlson, G.D., Goodwin,

<sup>2017.</sup> Resting-state connectivity biomarkers define neurophysiological subtypes of depression. NatMed 23, 28-38.

- 846 G.M., Kugel, H., Whalley, H.C., Ruhe, H.G., Soares, J.C., Fullerton, J.M., Rybakowski, J.K., Savitz,
- J., Chaim, K.T., Fatjo-Vilas, M., Soeiro-de-Souza, M.G., Boks, M.P., Zanetti, M.V., Otaduy, M.C.G.,
- Schaufelberger, M.S., Alda, M., Ingvar, M., Phillips, M.L., Kempton, M.J., Bauer, M., Landen, M.,
- Lawrence, N.S., van Haren, N.E.M., Horn, N.R., Freimer, N.B., Gruber, O., Schofield, P.R., Mitchell,
- 850 P.B., Kahn, R.S., Lenroot, R., Machado-Vieira, R., Ophoff, R.A., Sarro, S., Frangou, S., Satterthwaite,
- 851 T.D., Hajek, T., Dannlowski, U., Malt, U.F., Arolt, V., Gattaz, W.F., Drevets, W.C., Caseras, X.,
- Agartz, I., Thompson, P.M., Andreassen, O.A., 2018. Cortical abnormalities in bipolar disorder: an
  MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol
  Psychiatry 23, 932-942.
- Iwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., Senda, M., Ito, K., Ikeuchi, T., Kuwano,
  R., Matsuda, H., Japanese Alzheimer's Disease Neuroimaging, I., Sun, C.K., Beckett, L.A., Petersen,
  R.C., Weiner, M.W., Aisen, P.S., Donohue, M.C., Alzheimer's Disease Neuroimaging, I., 2018.
  Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization
  for international trials. Alzheimers Dement 14, 1077-1087.
- Koike, S., Takano, Y., Iwashiro, N., Satomura, Y., Suga, M., Nagai, T., Natsubori, T., Tada, M.,
  Nishimura, Y., Yamasaki, S., Takizawa, R., Yahata, N., Araki, T., Yamasue, H., Kasai, K., 2013. A
  multimodal approach to investigate biomarkers for psychosis in a clinical setting: the Integrative
  Neuroimaging studies in Schizophrenia Targeting for Early intervention and Prevention (IN-STEP)
  project Schizophr Res 143, 116-124.
- Koutsouleris, N., Meisenzahl, E.M., Borgwardt, S., Riecher-Rossler, A., Frodl, T., Kambeitz, J., Kohler,
  Y., Falkai, P., Moller, H.J., Reiser, M., Davatzikos, C., 2015. Individualized differential diagnosis of
  schizophrenia and mood disorders using neuroanatomical biomarkers. Brain 138, 2059-2073.
- Lee, T.Y., Kwon, J.S., 2016. Psychosis research in Asia: advantage from low prevalence of cannabis use.
  NPJ Schizophr 2, 1.
- Marcus, D.S., Harms, M.P., Snyder, A.Z., Jenkinson, M., Wilson, J.A., Glasser, M.F., Barch, D.M.,
  Archie, K.A., Burgess, G.C., Ramaratnam, M., Hodge, M., Horton, W., Herrick, R., Olsen, T.,
- Archie, K.A., Burgess, O.C., Kaharathan, M., Hodge, M., Horton, W., Herrick, K., Olsen, T.,
  McKay, M., House, M., Hileman, M., Reid, E., Harwell, J., Coalson, T., Schindler, J., Elam, J.S.,
  Curtiss, S.W., Van Essen, D.C., Consortium, W.U.-M.H., 2013. Human Connectome Project
- 874 informatics: quality control, database services, and data visualization. Neuroimage 80, 202-219.
  875 Million Million Million Allow Field Million Million
- Miller, K.L., Alfaro-Almagro, F., Bangerter, N.K., Thomas, D.L., Yacoub, E., Xu, J., Bartsch, A.J.,
  Jbabdi, S., Sotiropoulos, S.N., Andersson, J.L., Griffanti, L., Douaud, G., Okell, T.W., Weale, P.,
- B77 Dragonu, I., Garratt, S., Hudson, S., Collins, R., Jenkinson, M., Matthews, P.M., Smith, S.M., 2016.
  B78 Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat
  B79 Neurosci 19, 1523-1536.
- Moeller, S., Yacoub, E., Olman, C.A., Auerbach, E., Strupp, J., Harel, N., Ugurbil, K., 2010. Multiband
  multislice GE-EPI at 7 tesla, with 16-fold acceleration using partial parallel imaging with application
  to high spatial and temporal whole-brain fMRI. Magn Reson Med 63, 1144-1153.
- Mueller, S.G., Weiner, M.W., Thal, L.J., Petersen, R.C., Jack, C., Jagust, W., Trojanowski, J.Q., Toga,
  A.W., Beckett, L., 2005. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am
  15, 869-877, xi-xii.
- Mukai, Y., Murata, M., 2017. Japan Parkinson's Progression Markers Initiative (J-PPMI). Nihon Rinsho
   75, 151-155.
- Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., Ezzati, M., Shibuya, K.,
  Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S.Y., Ali,
- 890 M.K., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddour, L.M.,
- Bahalim, A.N., Barker-Collo, S., Barrero, L.H., Bartels, D.H., Basanez, M.G., Baxter, A., Bell, M.L.,
- Benjamin, E.J., Bennett, D., Bernabe, E., Bhalla, K., Bhandari, B., Bikbov, B., Bin Abdulhak, A.,
- Birbeck, G., Black, J.A., Blencowe, H., Blore, J.D., Blyth, F., Bolliger, I., Bonaventure, A., Boufous,
- 894 S., Bourne, R., Boussinesq, M., Braithwaite, T., Brayne, C., Bridgett, L., Brooker, S., Brooks, P.,
- Brugha, T.S., Bryan-Hancock, C., Bucello, C., Buchbinder, R., Buckle, G., Budke, C.M., Burch, M.,
- Burney, P., Burstein, R., Calabria, B., Campbell, B., Canter, C.E., Carabin, H., Carapetis, J., Carmona,


897 L., Cella, C., Charlson, F., Chen, H., Cheng, A.T., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., 898 Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., 899 de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahiya, M., 900 Dahodwala, N., Damsere-Derry, J., Danaei, G., Davis, A., De Leo, D., Degenhardt, L., Dellavalle, R., Delossantos, A., Denenberg, J., Derrett, S., Des Jarlais, D.C., Dharmaratne, S.D., Dherani, M., Diaz-901 902 Torne, C., Dolk, H., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Edmond, K., Elbaz, A., Ali, S.E., 903 Erskine, H., Erwin, P.J., Espindola, P., Ewoigbokhan, S.E., Farzadfar, F., Feigin, V., Felson, D.T., 904 Ferrari, A., Ferri, C.P., Fevre, E.M., Finucane, M.M., Flaxman, S., Flood, L., Foreman, K., 905 Forouzanfar, M.H., Fowkes, F.G., Fransen, M., Freeman, M.K., Gabbe, B.J., Gabriel, S.E., Gakidou, 906 E., Ganatra, H.A., Garcia, B., Gaspari, F., Gillum, R.F., Gmel, G., Gonzalez-Medina, D., Gosselin, R., 907 Grainger, R., Grant, B., Groeger, J., Guillemin, F., Gunnell, D., Gupta, R., Haagsma, J., Hagan, H., 908 Halasa, Y.A., Hall, W., Haring, D., Haro, J.M., Harrison, J.E., Havmoeller, R., Hay, R.J., Higashi, H., 909 Hill, C., Hoen, B., Hoffman, H., Hotez, P.J., Hoy, D., Huang, J.J., Ibeanusi, S.E., Jacobsen, K.H., 910 James, S.L., Jarvis, D., Jasrasaria, R., Javaraman, S., Johns, N., Jonas, J.B., Karthikevan, G., 911 Kassebaum, N., Kawakami, N., Keren, A., Khoo, J.P., King, C.H., Knowlton, L.M., Kobusingve, O., 912 Koranteng, A., Krishnamurthi, R., Laden, F., Lalloo, R., Laslett, L.L., Lathlean, T., Leasher, J.L., Lee, 913 Y.Y., Leigh, J., Levinson, D., Lim, S.S., Limb, E., Lin, J.K., Lipnick, M., Lipshultz, S.E., Liu, W., 914 Loane, M., Ohno, S.L., Lyons, R., Mabweijano, J., MacIntyre, M.F., Malekzadeh, R., Mallinger, L., 915 Manivannan, S., Marcenes, W., March, L., Margolis, D.J., Marks, G.B., Marks, R., Matsumori, A., 916 Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGill, N., McGrath, J., 917 Medina-Mora, M.E., Meltzer, M., Mensah, G.A., Merriman, T.R., Meyer, A.C., Miglioli, V., Miller, 918 M., Miller, T.R., Mitchell, P.B., Mock, C., Mocumbi, A.O., Moffitt, T.E., Mokdad, A.A., Monasta, L., 919 Montico, M., Moradi-Lakeh, M., Moran, A., Morawska, L., Mori, R., Murdoch, M.E., Mwaniki, M.K., 920 Naidoo, K., Nair, M.N., Naldi, L., Naravan, K.M., Nelson, P.K., Nelson, R.G., Nevitt, M.C., Newton, 921 C.R., Nolte, S., Norman, P., Norman, R., O'Donnell, M., O'Hanlon, S., Olives, C., Omer, S.B., 922 Ortblad, K., Osborne, R., Ozgediz, D., Page, A., Pahari, B., Pandian, J.D., Rivero, A.P., Patten, S.B., 923 Pearce, N., Padilla, R.P., Perez-Ruiz, F., Perico, N., Pesudovs, K., Phillips, D., Phillips, M.R., Pierce, 924 K., Pion, S., Polanczyk, G.V., Polinder, S., Pope, C.A., 3rd, Popova, S., Porrini, E., Pourmalek, F., 925 Prince, M., Pullan, R.L., Ramaiah, K.D., Ranganathan, D., Razavi, H., Regan, M., Rehm, J.T., Rein, 926 D.B., Remuzzi, G., Richardson, K., Rivara, F.P., Roberts, T., Robinson, C., De Leon, F.R., Ronfani, 927 L., Room, R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Saha, S., Sampson, U., Sanchez-Riera, L., 928 Sanman, E., Schwebel, D.C., Scott, J.G., Segui-Gomez, M., Shahraz, S., Shepard, D.S., Shin, H., 929 Shivakoti, R., Singh, D., Singh, G.M., Singh, J.A., Singleton, J., Sleet, D.A., Sliwa, K., Smith, E., 930 Smith, J.L., Stapelberg, N.J., Steer, A., Steiner, T., Stolk, W.A., Stovner, L.J., Sudfeld, C., Syed, S., 931 Tamburlini, G., Tavakkoli, M., Taylor, H.R., Taylor, J.A., Taylor, W.J., Thomas, B., Thomson, W.M., 932 Thurston, G.D., Tleyjeh, I.M., Tonelli, M., Towbin, J.A., Truelsen, T., Tsilimbaris, M.K., Ubeda, C., 933 Undurraga, E.A., van der Werf, M.J., van Os, J., Vavilala, M.S., Venketasubramanian, N., Wang, M., 934 Wang, W., Watt, K., Weatherall, D.J., Weinstock, M.A., Weintraub, R., Weisskopf, M.G., Weissman, 935 M.M., White, R.A., Whiteford, H., Wiebe, N., Wiersma, S.T., Wilkinson, J.D., Williams, H.C., 936 Williams, S.R., Witt, E., Wolfe, F., Woolf, A.D., Wulf, S., Yeh, P.H., Zaidi, A.K., Zheng, Z.J., Zonies, 937 D., Lopez, A.D., AlMazroa, M.A., Memish, Z.A., 2012. Disability-adjusted life years (DALYs) for 938 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of 939 Disease Study 2010. Lancet 380, 2197-2223. 940 Nunes, A., Schnack, H.G., Ching, C.R.K., Agartz, I., Akudjedu, T.N., Alda, M., Alnaes, D., Alonso-Lana, 941 S., Bauer, J., Baune, B.T., Boen, E., Bonnin, C.D.M., Busatto, G.F., Canales-Rodriguez, E.J., Cannon, 942 D.M., Caseras, X., Chaim-Avancini, T.M., Dannlowski, U., Diaz-Zuluaga, A.M., Dietsche, B., Doan, 943 N.T., Duchesnay, E., Elvsashagen, T., Emden, D., Eyler, L.T., Fatjo-Vilas, M., Favre, P., Foley, S.F.,


- 944 Fullerton, J.M., Glahn, D.C., Goikolea, J.M., Grotegerd, D., Hahn, T., Henry, C., Hibar, D.P.,
- 945 Houenou, J., Howells, F.M., Jahanshad, N., Kaufmann, T., Kenney, J., Kircher, T.T.J., Krug, A.,
- 946 Lagerberg, T.V., Lenroot, R.K., Lopez-Jaramillo, C., Machado-Vieira, R., Malt, U.F., McDonald, C.,
- 947 Mitchell, P.B., Mwangi, B., Nabulsi, L., Opel, N., Overs, B.J., Pineda-Zapata, J.A., Pomarol-Clotet,


- 948 E., Redlich, R., Roberts, G., Rosa, P.G., Salvador, R., Satterthwaite, T.D., Soares, J.C., Stein, D.J.,
- 949 Temmingh, H.S., Trappenberg, T., Uhlmann, A., van Haren, N.E.M., Vieta, E., Westlye, L.T., Wolf,
- 950 D.H., Yuksel, D., Zanetti, M.V., Andreassen, O.A., Thompson, P.M., Hajek, T., Group, E.B.D.W.,
- 2018. Using structural MRI to identify bipolar disorders 13 site machine learning study in 3020
   individuals from the ENIGMA Bipolar Disorders Working Group. Mol Psychiatry.
- O'Shea, A., Cohen, R.A., Porges, E.C., Nissim, N.R., Woods, A.J., 2016. Cognitive Aging and the
  Hippocampus in Older Adults. Front Aging Neurosci 8, 298.
- Okada, N., Ando, S., Sanada, M., Hirata-Mogi, S., Iijima, Y., Sugiyama, H., Shirakawa, T., Yamagishi,
  M., Kanehara, A., Morita, M., Yagi, T., Hayashi, N., Koshiyama, D., Morita, K., Sawada, K.,
- 957 Ikegame, T., Sugimoto, N., Toriyama, R., Masaoka, M., Fujikawa, S., Kanata, S., Tada, M., Kirihara,
- 958 K., Yahata, N., Araki, T., Jinde, S., Kano, Y., Koike, S., Endo, K., Yamasaki, S., Nishida, A., Hiraiwa-
- Hasegawa, M., Bundo, M., Iwamoto, K., Tanaka, S.C., Kasai, K., 2019. Population-neuroscience
  study of the Tokyo TEEN Cohort (pn-TTC): Cohort longitudinal study to explore the neurobiological
- 961 substrates of adolescent psychological and behavioral development. Psychiatry Clin Neurosci 73, 231962 242.
- 963 Okada, N., Fukunaga, M., Yamashita, F., Koshiyama, D., Yamamori, H., Ohi, K., Yasuda, Y., Fujimoto,
  964 M., Watanabe, Y., Yahata, N., Nemoto, K., Hibar, D.P., van Erp, T.G., Fujino, H., Isobe, M., Isomura,
- 965 S., Natsubori, T., Narita, H., Hashimoto, N., Miyata, J., Koike, S., Takahashi, T., Yamasue, H.,
- Matsuo, K., Onitsuka, T., Iidaka, T., Kawasaki, Y., Yoshimura, R., Watanabe, Y., Suzuki, M., Turner,
  J.A., Takeda, M., Thompson, P.M., Ozaki, N., Kasai, K., Hashimoto, R., 2016. Abnormal asymmetries
  in subcortical brain volume in schizophrenia. Mol Psychiatry 21, 1460-1466.
- Parkinson Progression Marker Initiative, 2011. The Parkinson Progression Marker Initiative (PPMI). Prog
   Neurobiol 95, 629-635.
- 971 R Core Team, 2018. R: A language and environment for statistical computing. R Foundation for
   972 Statistical Computing. Vienna, Austria.
- 873 Robinson, E.C., Garcia, K., Glasser, M.F., Chen, Z., Coalson, T.S., Makropoulos, A., Bozek, J., Wright,
  874 R., Schuh, A., Webster, M., Hutter, J., Price, A., Cordero Grande, L., Hughes, E., Tusor, N., Bayly,
  875 P.V., Van Essen, D.C., Smith, S.M., Edwards, A.D., Hajnal, J., Jenkinson, M., Glocker, B., Rueckert,
  876 D. 2019, M. Kinghal, M. Kinghal, J., Jenkinson, M., Glocker, B., Rueckert,
- 976 D., 2018. Multimodal surface matching with higher-order smoothness constraints. Neuroimage 167, 453-465.
- 978 Sadato, N., Morita, K., Kasai, K., Fukushi, T., Nakamura, K., Nakazawa, E., Okano, H., Okabe, S., 2019.
  979 Neuroethical Issues of the Brain/MINDS Project of Japan. Neuron 101, 385-389.
- Salimi-Khorshidi, G., Douaud, G., Beckmann, C.F., Glasser, M.F., Griffanti, L., Smith, S.M., 2014.
  Automatic denoising of functional MRI data: combining independent component analysis and hierarchical fusion of classifiers. Neuroimage 90, 449-468.
- Schmaal, L., Hibar, D.P., Samann, P.G., Hall, G.B., Baune, B.T., Jahanshad, N., Cheung, J.W., van Erp,
  T.G.M., Bos, D., Ikram, M.A., Vernooij, M.W., Niessen, W.J., Tiemeier, H., Hofman, A., Wittfeld,
- 985 K., Grabe, H.J., Janowitz, D., Bulow, R., Selonke, M., Volzke, H., Grotegerd, D., Dannlowski, U.,
- 986 Arolt, V., Opel, N., Heindel, W., Kugel, H., Hoehn, D., Czisch, M., Couvy-Duchesne, B., Renteria,
- 987 M.E., Strike, L.T., Wright, M.J., Mills, N.T., de Zubicaray, G.I., McMahon, K.L., Medland, S.E.,
- 988 Martin, N.G., Gillespie, N.A., Goya-Maldonado, R., Gruber, O., Kramer, B., Hatton, S.N.,
- 989 Lagopoulos, J., Hickie, I.B., Frodl, T., Carballedo, A., Frey, E.M., van Velzen, L.S., Penninx, B., van
- Tol, M.J., van der Wee, N.J., Davey, C.G., Harrison, B.J., Mwangi, B., Cao, B., Soares, J.C., Veer,
- 991 I.M., Walter, H., Schoepf, D., Zurowski, B., Konrad, C., Schramm, E., Normann, C., Schnell, K.,
- 992 Sacchet, M.D., Gotlib, I.H., MacQueen, G.M., Godlewska, B.R., Nickson, T., McIntosh, A.M.,
- 993 Papmeyer, M., Whalley, H.C., Hall, J., Sussmann, J.E., Li, M., Walter, M., Aftanas, L., Brack, I.,
- Bokhan, N.A., Thompson, P.M., Veltman, D.J., 2017. Cortical abnormalities in adults and adolescents
- with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA MajorDepressive Disorder Working Group. Mol Psychiatry 22, 900-909.
- Schmaal, L., Veltman, D.J., van Erp, T.G., Samann, P.G., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier,
  H., Hofman, A., Niessen, W.J., Vernooij, M.W., Ikram, M.A., Wittfeld, K., Grabe, H.J., Block, A.,

- 999 Hegenscheid, K., Volzke, H., Hoehn, D., Czisch, M., Lagopoulos, J., Hatton, S.N., Hickie, I.B., Goya-
- 1000 Maldonado, R., Kramer, B., Gruber, O., Couvy-Duchesne, B., Renteria, M.E., Strike, L.T., Mills,
- 1001 N.T., de Zubicaray, G.I., McMahon, K.L., Medland, S.E., Martin, N.G., Gillespie, N.A., Wright, M.J.,
- Hall, G.B., MacQueen, G.M., Frey, E.M., Carballedo, A., van Velzen, L.S., van Tol, M.J., van der
- 1003 Wee, N.J., Veer, I.M., Walter, H., Schnell, K., Schramm, E., Normann, C., Schoepf, D., Konrad, C.,
- 1004 Zurowski, B., Nickson, T., McIntosh, A.M., Papmeyer, M., Whalley, H.C., Sussmann, J.E.,
- 1005 Godlewska, B.R., Cowen, P.J., Fischer, F.H., Rose, M., Penninx, B.W., Thompson, P.M., Hibar, D.P.,
- 2016. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major
   Depressive Disorder working group. Mol Psychiatry 21, 806-812.
- Setsompop, K., Gagoski, B.A., Polimeni, J.R., Witzel, T., Wedeen, V.J., Wald, L.L., 2012. Blippedcontrolled aliasing in parallel imaging for simultaneous multislice echo planar imaging with reduced
  g-factor penalty. Magn Reson Med 67, 1210-1224.
- Smith, S.M., Nichols, T.E., Vidaurre, D., Winkler, A.M., Behrens, T.E., Glasser, M.F., Ugurbil, K.,
  Barch, D.M., Van Essen, D.C., Miller, K.L., 2015. A positive-negative mode of population covariation
  links brain connectivity, demographics and behavior. Nat Neurosci 18, 1565-1567.
- Somerville, L.H., Bookheimer, S.Y., Buckner, R.L., Burgess, G.C., Curtiss, S.W., Dapretto, M., Elam,
  J.S., Gaffrey, M.S., Harms, M.P., Hodge, C., Kandala, S., Kastman, E.K., Nichols, T.E., Schlaggar,
  B.L., Smith, S.M., Thomas, K.M., Yacoub, E., Van Essen, D.C., Barch, D.M., 2018. The Lifespan
  Human Connectome Project in Development: A large-scale study of brain connectivity development
- 1018 in 5-21 year olds. Neuroimage 183, 456-468.
- Sotiropoulos, S.N., Hernandez-Fernandez, M., Vu, A.T., Andersson, J.L., Moeller, S., Yacoub, E.,
  Lenglet, C., Ugurbil, K., Behrens, T.E.J., Jbabdi, S., 2016. Fusion in diffusion MRI for improved fibre
  orientation estimation: An application to the 3T and 7T data of the Human Connectome Project.
  Neuroimage 134, 396-409.
- van Erp, T.G., Hibar, D.P., Rasmussen, J.M., Glahn, D.C., Pearlson, G.D., Andreassen, O.A., Agartz, I.,
  Westlye, L.T., Haukvik, U.K., Dale, A.M., Melle, I., Hartberg, C.B., Gruber, O., Kraemer, B., Zilles,
  D., Donohoe, G., Kelly, S., McDonald, C., Morris, D.W., Cannon, D.M., Corvin, A., Machielsen,
- D., Donohoe, G., Kelly, S., McDonald, C., Morris, D.W., Cannon, D.M., Corvin, A., Machielsen,
  M.W., Koenders, L., de Haan, L., Veltman, D.J., Satterthwaite, T.D., Wolf, D.H., Gur, R.C., Gur,
- 1027 N. W., Koenders, L., de Haan, L., Vennan, D.J., Satterniwate, T.D., won, D.H., Gur, K.C., Gur, R.E., Potkin, S.G., Mathalon, D.H., Mueller, B.A., Preda, A., Macciardi, F., Ehrlich, S., Walton, E.,
- Hass, J., Calhoun, V.D., Bockholt, H.J., Sponheim, S.R., Shoemaker, J.M., van Haren, N.E., Hulshoff
- 1029 Pol, H.E., Ophoff, R.A., Kahn, R.S., Roiz-Santianez, R., Crespo-Facorro, B., Wang, L., Alpert, K.I.,
- Jonsson, E.G., Dimitrova, R., Bois, C., Whalley, H.C., McIntosh, A.M., Lawrie, S.M., Hashimoto, R.,
   Thompson, P.M., Turner, J.A., 2016. Subcortical brain volume abnormalities in 2028 individuals with
   schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry 21, 547-553.
- schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry 21, 547-553.
  Van Essen, D.C., Ugurbil, K., Auerbach, E., Barch, D., Behrens, T.E., Bucholz, R., Chang, A., Chen, L.,
- Corbetta, M., Curtiss, S.W., Della Penna, S., Feinberg, D., Glasser, M.F., Harel, N., Heath, A.C.,
  Larson-Prior, L., Marcus, D., Michalareas, G., Moeller, S., Oostenveld, R., Petersen, S.E., Prior, F.,
  Schlaggar, B.L., Smith, S.M., Snyder, A.Z., Xu, J., Yacoub, E., Consortium, W.U.-M.H., 2012. The
  Human Connectome Project: a data acquisition perspective. Neuroimage 62, 2222-2231.
- Wang, Y., Xu, Q., Luo, J., Hu, M., Zuo, C., 2019. Effects of Age and Sex on Subcortical Volumes. Front
  Aging Neurosci 11, 259.
- Weiner, M.W., Veitch, D.P., Aisen, P.S., Beckett, L.A., Cairns, N.J., Cedarbaum, J., Green, R.C., Harvey,
  D., Jack, C.R., Jagust, W., Luthman, J., Morris, J.C., Petersen, R.C., Saykin, A.J., Shaw, L., Shen, L.,
  Schwarz, A., Toga, A.W., Trojanowski, J.Q., Alzheimer's Disease Neuroimaging, I., 2015. 2014
  Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its
- 1044 inception. Alzheimers Dement 11, e1-120.
- Winter, W., Sheridan, M., 2014. Previous reward decreases errors of commission on later 'No-Go' trials in
  children 4 to 12 years of age: evidence for a context monitoring account. Dev Sci 17, 797-807.
- 1047 Xu, J., Moeller, S., Auerbach, E.J., Strupp, J., Smith, S.M., Feinberg, D.A., Yacoub, E., Ugurbil, K.,
- 2013. Evaluation of slice accelerations using multiband echo planar imaging at 3 T. Neuroimage 83, 991-1001.

- 1050 Yahata, N., Morimoto, J., Hashimoto, R., Lisi, G., Shibata, K., Kawakubo, Y., Kuwabara, H., Kuroda,
- 1051 M., Yamada, T., Megumi, F., Imamizu, H., Nanez, J.E., Sr., Takahashi, H., Okamoto, Y., Kasai, K.,
- Kato, N., Sasaki, Y., Watanabe, T., Kawato, M., 2016. A small number of abnormal brain connections
  predicts adult autism spectrum disorder. Nat Commun 7, 11254.
- Yamashita, A., Yahata, N., Itahashi, T., Lisi, G., Yamada, T., Ichikawa, N., Takamura, M., Yoshihara, Y.,
  Kunimatsu, A., Okada, N., Yamagata, H., Matsuo, K., Hashimoto, R., Okada, G., Sakai, Y.,
- 1056 Morimoto, J., Narumoto, J., Shimada, Y., Kasai, K., Kato, N., Takahashi, H., Okamoto, Y., Tanaka,
- 1057 S.C., Kawato, M., Yamashita, O., Imamizu, H., 2019. Harmonization of resting-state functional MRI
- data across multiple imaging sites via the separation of site differences into sampling bias and
   measurement bias. PLoS Biol 17, e3000042.
- Zhang, H., Schneider, T., Wheeler-Kingshott, C.A., Alexander, D.C., 2012. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 61, 1000-1016.
- 1062







Temporal Signal-to-Noise Ratio (tSNR)

1.6

3.0

